Tumors or cancer of the LUNG.
Corrosive oxidant, explosive; additive to diesel and rocket fuels; causes skin and lung irritation; proposed war gas. A useful reagent for studying the modification of specific amino acids, particularly tyrosine residues in proteins. Has also been used for studying carbanion formation and for detecting the presence of double bonds in organic compounds.
Toxic, possibly carcinogenic, monomer of neoprene, a synthetic rubber; causes damage to skin, lungs, CNS, kidneys, liver, blood cells and fetuses. Synonym: 2-chlorobutadiene.
Materials applied to fabrics, bedding, furniture, plastics, etc. to retard their burning; many may leach out and cause allergies or other harm.
A carcinoma thought to be derived from epithelium of terminal bronchioles, in which the neoplastic tissue extends along the alveolar walls and grows in small masses within the alveoli. Involvement may be uniformly diffuse and massive, or nodular, or lobular. The neoplastic cells are cuboidal or columnar and form papillary structures. Mucin may be demonstrated in some of the cells and in the material in the alveoli, which also includes denuded cells. Metastases in regional lymph nodes, and in even more distant sites, are known to occur, but are infrequent. (From Stedman, 25th ed)
Derivatives of propylene glycol (1,2-propanediol). They are used as humectants and solvents in pharmaceutical preparations.
Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood.
Family of retrovirus-associated DNA sequences (ras) originally isolated from Harvey (H-ras, Ha-ras, rasH) and Kirsten (K-ras, Ki-ras, rasK) murine sarcoma viruses. Ras genes are widely conserved among animal species and sequences corresponding to both H-ras and K-ras genes have been detected in human, avian, murine, and non-vertebrate genomes. The closely related N-ras gene has been detected in human neuroblastoma and sarcoma cell lines. All genes of the family have a similar exon-intron structure and each encodes a p21 protein.
Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation.
A set of three nucleotides in a protein coding sequence that specifies individual amino acids or a termination signal (CODON, TERMINATOR). Most codons are universal, but some organisms do not produce the transfer RNAs (RNA, TRANSFER) complementary to all codons. These codons are referred to as unassigned codons (CODONS, NONSENSE).
Pathological processes involving any part of the LUNG.
Damage to any compartment of the lung caused by physical, chemical, or biological agents which characteristically elicit inflammatory reaction. These inflammatory reactions can either be acute and dominated by NEUTROPHILS, or chronic and dominated by LYMPHOCYTES and MACROPHAGES.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
The transference of either one or both of the lungs from one human or animal to another.
Neoplasms containing cyst-like formations or producing mucin or serum.
A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).
Tumors or cancer of the SKIN.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
Measurement of the amount of air that the lungs may contain at various points in the respiratory cycle.
Tumors or cancers of the KIDNEY.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.
A malignant epithelial tumor with a glandular organization.
Tumors or cancer of the THYROID GLAND.
DNA present in neoplastic tissue.
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Tumors or cancer of the LIVER.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
Tumors or cancer of the PAROTID GLAND.
A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)
Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue.
Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.
Tumors or cancer of the APPENDIX.
The volume of air contained in the lungs at the end of a maximal inspiration. It is the equivalent to each of the following sums: VITAL CAPACITY plus RESIDUAL VOLUME; INSPIRATORY CAPACITY plus FUNCTIONAL RESIDUAL CAPACITY; TIDAL VOLUME plus INSPIRATORY RESERVE VOLUME plus functional residual capacity; or tidal volume plus inspiratory reserve volume plus EXPIRATORY RESERVE VOLUME plus residual volume.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Small polyhedral outpouchings along the walls of the alveolar sacs, alveolar ducts and terminal bronchioles through the walls of which gas exchange between alveolar air and pulmonary capillary blood takes place.
Water content outside of the lung vasculature. About 80% of a normal lung is made up of water, including intracellular, interstitial, and blood water. Failure to maintain the normal homeostatic fluid exchange between the vascular space and the interstitium of the lungs can result in PULMONARY EDEMA and flooding of the alveolar space.
A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
Tumors, cancer or other neoplasms produced by exposure to ionizing or non-ionizing radiation.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)
Tumors or cancer of the ENDOCRINE GLANDS.
Washing liquid obtained from irrigation of the lung, including the BRONCHI and the PULMONARY ALVEOLI. It is generally used to assess biochemical, inflammatory, or infection status of the lung.
Tumors or cancer of the NOSE.
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).
An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)
A benign epithelial tumor with a glandular organization.
Tumors or cancer of the EYE.
Neoplasms composed of vascular tissue. This concept does not refer to neoplasms located in blood vessels.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Tumors or cancer of the SALIVARY GLANDS.
Tumors or cancer located in bone tissue or specific BONES.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.
Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.
Neoplasms composed of muscle tissue: skeletal, cardiac, or smooth. The concept does not refer to neoplasms located in muscles.
Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
Tumors or cancer of the UTERUS.
Solitary or multiple collections of PUS within the lung parenchyma as a result of infection by bacteria, protozoa, or other agents.
A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)
A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
A general term for various neoplastic diseases of the lymphoid tissue.
Tumors or cancer of the INTESTINES.
Neoplasms located in the vasculature system, such as ARTERIES and VEINS. They are differentiated from neoplasms of vascular tissue (NEOPLASMS, VASCULAR TISSUE), such as ANGIOFIBROMA or HEMANGIOMA.
Neoplasms composed of sebaceous or sweat gland tissue or tissue of other skin appendages. The concept does not refer to neoplasms located in the sebaceous or sweat glands or in the other skin appendages.
Lung damage that is caused by the adverse effects of PULMONARY VENTILATOR usage. The high frequency and tidal volumes produced by a mechanical ventilator can cause alveolar disruption and PULMONARY EDEMA.
Neoplasms composed of more than one type of neoplastic tissue.
Tumors or cancer of the COLON.
Tumors or cancer of the PALATE, including those of the hard palate, soft palate and UVULA.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Tumors or cancer of the MANDIBLE.
Tumors or cancer of the THYMUS GLAND.
Tumors or cancer of the SPLEEN.
A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)
Tumors or cancer of the BILE DUCTS.
Tumors in any part of the heart. They include primary cardiac tumors and metastatic tumors to the heart. Their interference with normal cardiac functions can cause a wide variety of symptoms including HEART FAILURE; CARDIAC ARRHYTHMIAS; or EMBOLISM.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Diseases of the domestic dog (Canis familiaris). This term does not include diseases of wild dogs, WOLVES; FOXES; and other Canidae for which the heading CARNIVORA is used.
Measurement of the various processes involved in the act of respiration: inspiration, expiration, oxygen and carbon dioxide exchange, lung volume and compliance, etc.
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
A cystic tumor of the ovary, containing thin, clear, yellow serous fluid and varying amounts of solid tissue, with a malignant potential several times greater than that of mucinous cystadenoma (CYSTADENOMA, MUCINOUS). It can be unilocular, parvilocular, or multilocular. It is often bilateral and papillary. The cysts may vary greatly in size. (Dorland, 27th ed; from Hughes, Obstetric-Gynecologic Terminology, 1972)
Infection of the lung often accompanied by inflammation.
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
Cancer or tumors of the MAXILLA or upper jaw.
The excision of lung tissue including partial or total lung lobectomy.
Any disorder marked by obstruction of conducting airways of the lung. AIRWAY OBSTRUCTION may be acute, chronic, intermittent, or persistent.
Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.
Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.
Tumors or cancer of the anal gland.
Neoplasms of the thin serous membrane that envelopes the lungs and lines the thoracic cavity. Pleural neoplasms are exceedingly rare and are usually not diagnosed until they are advanced because in the early stages they produce no symptoms.
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
Tumors or cancer of the MEDIASTINUM.
Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.
Excessive accumulation of extravascular fluid in the lung, an indication of a serious underlying disease or disorder. Pulmonary edema prevents efficient PULMONARY GAS EXCHANGE in the PULMONARY ALVEOLI, and can be life-threatening.
Neoplasms composed of fatty tissue or connective tissue made up of fat cells in a meshwork of areolar tissue. The concept does not refer to neoplasms located in adipose tissue.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
A form of alveolitis or pneumonitis due to an acquired hypersensitivity to inhaled antigens associated with farm environment. Antigens in the farm dust are commonly from bacteria actinomycetes (SACCHAROPOLYSPORA and THERMOACTINOMYCES), fungi, and animal proteins in the soil, straw, crops, pelts, serum, and excreta.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Tumors or cancer of the DUODENUM.
A cell line derived from cultured tumor cells.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
Inhaling and exhaling the smoke of burning TOBACCO.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Tumors or cancer of the MOUTH.
Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included.
A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.
A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.
Tumors or cancer of the STOMACH.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
Tumors or cancer of the human BREAST.
Tumors or cancers of the ADRENAL CORTEX.
The circulation of the BLOOD through the LUNGS.
Tumors or cancer of the URINARY BLADDER.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Tumors or cancer of the TONGUE.
Tumors or cancer located in muscle tissue or specific muscles. They are differentiated from NEOPLASMS, MUSCLE TISSUE which are neoplasms composed of skeletal, cardiac, or smooth muscle tissue, such as MYOSARCOMA or LEIOMYOMA.
A rare malignant neoplasm characterized by rapidly proliferating, extensively infiltrating, anaplastic cells derived from blood vessels and lining irregular blood-filled or lumpy spaces. (Stedman, 25th ed)
Tumors or cancer in the ILEUM region of the small intestine (INTESTINE, SMALL).
A malignant tumor arising from secreting cells of a racemose gland, particularly the salivary glands. Racemose (Latin racemosus, full of clusters) refers, as does acinar (Latin acinus, grape), to small saclike dilatations in various glands. Acinar cell carcinomas are usually well differentiated and account for about 13% of the cancers arising in the parotid gland. Lymph node metastasis occurs in about 16% of cases. Local recurrences and distant metastases many years after treatment are common. This tumor appears in all age groups and is most common in women. (Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1240; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575)
Experimentally induced tumors of the LIVER.
Benign and malignant neoplastic processes arising from or involving components of the central, peripheral, and autonomic nervous systems, cranial nerves, and meninges. Included in this category are primary and metastatic nervous system neoplasms.
Benign and malignant neoplasms which occur within the substance of the spinal cord (intramedullary neoplasms) or in the space between the dura and spinal cord (intradural extramedullary neoplasms). The majority of intramedullary spinal tumors are primary CNS neoplasms including ASTROCYTOMA; EPENDYMOMA; and LIPOMA. Intramedullary neoplasms are often associated with SYRINGOMYELIA. The most frequent histologic types of intradural-extramedullary tumors are MENINGIOMA and NEUROFIBROMA.
The larger air passages of the lungs arising from the terminal bifurcation of the TRACHEA. They include the largest two primary bronchi which branch out into secondary bronchi, and tertiary bronchi which extend into BRONCHIOLES and PULMONARY ALVEOLI.
Enlargement of air spaces distal to the TERMINAL BRONCHIOLES where gas-exchange normally takes place. This is usually due to destruction of the alveolar wall. Pulmonary emphysema can be classified by the location and distribution of the lesions.
Tumors or cancer of the VAGINA.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
Substances and drugs that lower the SURFACE TENSION of the mucoid layer lining the PULMONARY ALVEOLI.
A usually benign glandular tumor composed of oxyphil cells, large cells with small irregular nuclei and dense acidophilic granules due to the presence of abundant MITOCHONDRIA. Oxyphil cells, also known as oncocytes, are found in oncocytomas of the kidney, salivary glands, and endocrine glands. In the thyroid gland, oxyphil cells are known as Hurthle cells and Askanazy cells.
A Janus kinase subtype that is involved in signaling from GROWTH HORMONE RECEPTORS; PROLACTIN RECEPTORS; and a variety of CYTOKINE RECEPTORS such as ERYTHROPOIETIN RECEPTORS and INTERLEUKIN RECEPTORS. Dysregulation of Janus kinase 2 due to GENETIC TRANSLOCATIONS have been associated with a variety of MYELOPROLIFERATIVE DISORDERS.
The mucous membrane lining the RESPIRATORY TRACT, including the NASAL CAVITY; the LARYNX; the TRACHEA; and the BRONCHI tree. The respiratory mucosa consists of various types of epithelial cells ranging from ciliated columnar to simple squamous, mucous GOBLET CELLS, and glands containing both mucous and serous cells.
Clonal myeloid disorders that possess both dysplastic and proliferative features but are not properly classified as either MYELODYSPLASTIC SYNDROMES or MYELOPROLIFERATIVE DISORDERS.
Tumors or cancer of the PARANASAL SINUSES.
Surgical removal of the pancreas. (Dorland, 28th ed)
Neoplasms located in the brain ventricles, including the two lateral, the third, and the fourth ventricle. Ventricular tumors may be primary (e.g., CHOROID PLEXUS NEOPLASMS and GLIOMA, SUBEPENDYMAL), metastasize from distant organs, or occur as extensions of locally invasive tumors from adjacent brain structures.
Neoplasms which arise from peripheral nerve tissue. This includes NEUROFIBROMAS; SCHWANNOMAS; GRANULAR CELL TUMORS; and malignant peripheral NERVE SHEATH NEOPLASMS. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp1750-1)
Substances that inhibit or prevent the proliferation of NEOPLASMS.

Human papillomavirus DNA in adenosquamous carcinoma of the lung. (1/26018)

AIM: To investigate the presence of human papillomavirus (HPV) DNA in adenosquamous carcinoma of the lung--which is relatively common in Okinawa but not in mainland Japan--and examine its histological features. METHODS: Of 207 cases where primary lung cancers were surgically removed between January 1995 and June 1997 in Okinawa, 23 were adenosquamous carcinoma. HPV was detected by non-isotopic in situ hybridisation (NISH) and polymerase chain reaction (PCR) amplification with primers specific for E6 and E7 regions of the HPV genome. PCR products were analysed by Southern blotting. Immunohistochemical determination of high molecular weight cytokeratin (HMC) and involucrin was also carried out. RESULTS: 18 cases were positive for HPV DNA by PCR and NISH. HPV types 6, 11, 16, and 18 were found. Seven cases were dual positive for different types of HPV. Using NISH, HPV was also found in the squamous cell components and in neighbouring enlarged adenocarcinoma cells. The HMC and involucrin were demonstrated immunohistochemically in the same areas. CONCLUSIONS: HPV DNA was found in a high proportion (78.3%) of adenosquamous carcinomas in Okinawa, a region where HPV has previously been shown to be prevalent in squamous cell carcinoma of the lung. The adenocarcinoma cells adjacent to the squamous cell carcinoma component were enlarged and positive for HPV, HMC, and involucrin. This is thought to indicate the transition from adenocarcinoma to squamous cell carcinoma.  (+info)

Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma. (2/26018)

The association of p53 abnormalities with the prognosis of patients with non-small cell lung carcinoma (NSCLC) has been extensively investigated to date, however, this association is still controversial. Therefore, we investigated the prognostic significance of p53 mutations through exons 2 to 11 and p53 protein expression in 103 cases of stage I NSCLC. p53 mutations were detected in 49 of 103 (48%) tumors. Two separate mutations were detected in four tumors giving a total of 53 unique mutations in 49 tumors. Ten (19%) of mutations occurred outside exons 5-8. Positive immunohistochemical staining of p53 protein was detected in 41 of 103 (40%) tumors. The concordance rate between mutations and protein overexpression was only 69%. p53 mutations, but not expression, were significantly associated with a shortened survival of patients (P<0.001). Furthermore, we investigated the correlation between the types of p53 mutations and prognosis. p53 missense mutations rather than null mutations were associated with poor prognosis (P < 0.001 in missense mutations and P=0.243 in null mutations). These results indicated that p53 mutations, in particular missense mutations, rather than p53 expression could be a useful molecular marker for the prognosis of patients with surgically resected stage I NSCLC.  (+info)

Comparative efficacy of positron emission tomography with FDG and computed tomographic scanning in preoperative staging of non-small cell lung cancer. (3/26018)

OBJECTIVE: To determine the sensitivity, specificity, and accuracy of positron emission tomography with 2-fluorine-18-fluorodeoxyglucose (PET-FDG) in the preoperative staging (N and M staging) of patients with lung cancer. The authors wanted to compare the efficacy of PET scanning with currently used computed tomography (CT) scanning. MATERIALS AND METHODS: Results of whole-body PET-FDG imaging and CT scans were compared with histologic findings for the presence or absence of lymph node disease or metastatic sites. Sampling of mediastinal lymph nodes was performed using mediastinoscopy or thoracotomy. RESULTS: PET-FDG imaging was significantly more sensitive, specific, and accurate for detecting N disease than CT. PET changed N staging in 35% and M staging in 11% of patients. CT scans helped in accurate anatomic localization of 6/57 PET lymph node abnormalities. CONCLUSION: PET-FDG is a reliable method for preoperative staging of patients with lung cancer and would help to optimize management of these patients. Accurate lymph node staging of lung cancer may be ideally performed by simultaneous review of PET and CT scans.  (+info)

Overexpression of the multidrug resistance-associated protein (MRP1) in human heavy metal-selected tumor cells. (4/26018)

Cellular and molecular mechanisms involved in the resistance to cytotoxic heavy metals remain largely to be characterized in mammalian cells. To this end, we have analyzed a metal-resistant variant of the human lung cancer GLC4 cell line that we have selected by a step-wise procedure in potassium antimony tartrate. Antimony-selected cells, termed GLC4/Sb30 cells, poorly accumulated antimony through an enhanced cellular efflux of metal, thus suggesting up-regulation of a membrane export system in these cells. Indeed, GLC4/Sb30 cells were found to display a functional overexpression of the multidrug resistance-associated protein MRP1, a drug export pump, as demonstrated by Western blotting, reverse transcriptase-polymerase chain reaction and calcein accumulation assays. Moreover, MK571, a potent inhibitor of MRP1 activity, was found to markedly down-modulate resistance of GLC4/Sb30 cells to antimony and to decrease cellular export of the metal. Taken together, our data support the conclusion that overexpression of functional MRP1 likely represents one major mechanism by which human cells can escape the cytotoxic effects of heavy metals.  (+info)

Expression of tissue factor in non-small-cell lung cancers and its relationship to metastasis. (5/26018)

Tissue factor (TF) is an initiator of the extrinsic cascade of blood coagulation. Although recent studies have revealed a relationship between metastatic properties and TF expression in some neoplastic cells, the significance of TF in lung cancer, especially in non-small-cell lung cancer (NSCLC), is still unclear. In this study, TF was detected in NSCLC cell lines by functional study, Western blot analysis and immunocytochemical staining. TF levels in eight NSCLC cell lines were also quantitated by enzyme-linked immunosorbent assay (ELISA), and TF expression was evaluated in 55 specimens of surgically resected NSCLCs. NSCLC cell lines derived from metastatic lesions produced high levels of TF (48.3+/-23.5 ng 10(-6) cells, mean +/- s.e.m.), whereas those derived from primary lesions produced low levels of TF (0.2+/-0.1 ng 10(-6) cells). Immunohistochemical studies disclosed significantly stronger staining for TF in cells from NSCLC patients with metastasis than in those without metastasis. Among the 28 patients with metastasis, ten were strongly positive, 16 were moderately positive and two were negative for TF. In contrast, among the 27 patients without metastasis, only two were strongly positive, 18 were moderately positive and seven were negative for TF. Therefore, malignant cells from patients with lung cancer produce various levels of TF, and TF may play an important role in the metastatic process.  (+info)

Early death during chemotherapy in patients with small-cell lung cancer: derivation of a prognostic index for toxic death and progression. (6/26018)

Based on an increased frequency of early death (death within the first treatment cycle) in our two latest randomized trials of combination chemotherapy in small-cell lung cancer (SCLC), we wanted to identify patients at risk of early non-toxic death (ENTD) and early toxic death (ETD). Data were stored in a database and logistic regression analyses were performed to identify predictive factors for early death. During the first cycle, 118 out of 937 patients (12.6%) died. In 38 patients (4%), the cause of death was sepsis. Significant risk factors were age, performance status (PS), lactate dehydrogenase (LDH) and treatment with epipodophyllotoxins and platinum in the first cycle (EP). Risk factors for ENTD were age, PS and LDH. Extensive stage had a hazard ratio of 1.9 (P = 0.07). Risk factors for ETD were EP, PS and LDH, whereas age and stage were not. For EP, the hazard ratio was as high as 6.7 (P = 0.0001). We introduced a simple prognostic algorithm including performance status, LDH and age. Using a prognostic algorithm to exclude poor-risk patients from trials, we could minimize early death, improve long-term survival and increase the survival differences between different regimens. We suggest that other groups evaluate our algorithm and exclude poor prognosis patients from trials of dose intensification.  (+info)

Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise. (7/26018)

The assessment of symptom palliation is an essential component of many treatment comparisons in clinical trials, yet an extensive literature search revealed no consensus as to its precise definition, which could embrace relief of symptoms, time to their onset, duration, degree, as well as symptom control and prevention. In an attempt to assess the importance of these aspects and to compare different methods of analysis, we used one symptom (cough) from a patient self-assessment questionnaire (the Rotterdam Symptom Checklist) in a large (>300 patient) multicentre randomized clinical trial (conducted by the Medical Research Council Lung Cancer Working Party) of palliative chemotherapy in small-cell lung cancer. The regimens compared were a two-drug regimen (2D) and a four-drug regimen (4D). No differences were seen between the regimens in time of onset of palliation or its duration. The degree of palliation was strongly related to the initial severity: 90% of the patients with moderate or severe cough at baseline reported improvement, compared with only 53% of those with mild cough. Analyses using different landmark time points gave conflicting results: the 4D regimen was superior at 1 month and at 3 months, whereas at 2 months the 2D regimen appeared superior. When improvement at any time up to 3 months was considered, the 4D regimen showed a significant benefit (4D 79%, 2D 60%, P = 0.02). These findings emphasize the need for caution in interpreting results, and the importance of working towards a standard definition of symptom palliation. The current lack of specified criteria makes analysis and interpretation of trial results difficult, and comparison across trials impossible. A standard definition of palliation for use in the analysis of clinical trials data is proposed, which takes into account aspects of onset, duration and degree of palliation, and symptom improvement, control and prevention.  (+info)

Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors. (8/26018)

Three different membrane-type matrix metalloproteinases (MT1-, MT2-, and MT3-MMPs) are known to activate in vitro the zymogen of MMP-2 (pro-MMP-2, progelatinase A), which is one of the key MMPs in invasion and metastasis of various cancers. In the present study, we have examined production and activation of pro-MMP-2, expression of MT1-, MT2-, and MT3-MMPs and their correlation with pro-MMP-2 activation, and localization of MMP-2, MT1-MMP, and MT2-MMP in human astrocytic tumors. The sandwich enzyme immunoassay demonstrates that the production levels of pro-MMP-2 in the anaplastic astrocytomas and glioblastomas are significantly higher than that in the low-grade astrocytomas (P<0.05 and P<0.01, respectively), metastatic brain tumors (P<0.05), or normal brains (P<0.01). Gelatin zymography indicates that the pro-MMP-2 activation ratio is significantly higher in the glioblastomas than in other astrocytic tumors (P<0.01), metastatic brain tumors (P<0.01), and normal brains (P<0.01). The quantitative reverse transcription polymerase chain reaction analyses demonstrate that MT1-MMP and MT2-MMP are expressed predominantly in glioblastoma tissues (17/17 and 12/17 cases, respectively), and their expression levels increase significantly as tumor grade increases. MT3-MMP is detectable in both astrocytic tumor and normal brain tissues, but the mean expression level is approximately 50-fold lower compared with that of MT1-MMP and MT2-MMP in the glioblastomas. The activation ratio of pro-MMP-2 correlates directly with the expression levels of MT1-MMP and MT2-MMP but not MT3-MMP. In situ hybridization indicates that neoplastic astrocytes express MT1-MMP and MT2-MMP in the glioblastoma tissues (5/5 cases and 5/5 cases, respectively). Immunohistochemically, MT1-MMP and MT2-MMP are localized to the neoplastic astrocytes in glioblastoma samples (17/17 cases and 12/17 cases, respectively), which are also positive for MMP-2. In situ zymography shows gelatinolytic activity in the glioblastoma tissues but not in the normal brain tissues. These results suggest that both MT1-MMP and MT2-MMP play a key role in the activation of pro-MMP-2 in the human malignant astrocytic tumors and that the gelatinolytic activity is involved in the astrocytic tumor invasion.  (+info)

Veracyte Announces New Clinical Data Showing First-Ever Noninvasive Nasal Swab Test Can Enable Early Lung Cancer Detection and Diagnosis Data presented today at CHEST 2019 Annual Meeting; Company plans to begin making test available in early 2021 Conference call and webcast today at 5:00 p.m. ET to review third quarter 2019 Financial results and the new nasal swab test data Veracyte, Inc. (Nasdaq: VCYT) today announced preliminary clinical data showing that the companys noninvasive nasal swab test - the first of its kind - can enable early lung cancer detection and diagnosis so that more lives can be saved. The new findings specifically show that the novel genomic test can accurately classify lung cancer risk in patients with lung nodules so that these patients can obtain the prompt diagnosis and potential treatment they need or may be monitored noninvasively. The findings will be presented today at the annual meeting of the American College of Chest Physicians® (CHEST) in New Orleans. Early ...
A look at the following clinical trial: Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable Non-Small Cell Lung Cancer (NSCLC) or Metastatic Lung Tumours
A look at the following clinical trial: Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable Non-Small Cell Lung Cancer (NSCLC) or Metastatic Lung Tumours
Could the Neutrophil to Lymphocyte Ratio be a Poor Prognostic Factor for Non Small Cell Lung Cancers? Lung cancer;neutrophil to lymphocyte ratio;prognostic factors;C reactive protein; Background: Although many prognostic factors have been identified for lung cancers, new ones are needed to determine the course of the disease. Recently, a high neutrophil to lymphocyte ratio (NLR) prior to surgery or treatment has been shown to be an indicator of prognosis for cancer. The aim of this study was to investigate the value of NLR as a prognostic factor and the correlation between NLR and other probable clinical prognostic factors in non small cell lung cancer patients prior to treatment. Materials and Methods: Data of patients who were diagnosed with non-small cell lung cancer in our institution were retrospectively reviewed. Demographic and clinicopathologic characteristics were recorded. NLR was calculated before the application of any treatment. Results: A total of 299 patients, 270 (90%) males and 29 (10
Since this squamous cell lung cancer is being considered as destructive neoplasm in lungs, additional care is paid towards incorporating the effective supportive therapy in the regular anti cancerous therapy, involving multi drug combinations. The supportive therapy may include usage of suitable corticosteroid drugs like prednisolone in a routine form and it is noteworthy to mention that in some patients, a repository form of this corticosteroid may also be used to fulfill the need of constant delivery.. Surgery is also being considered as therapy in cases of squamous cell lung cancer. But, if the spread of this is over a wide area, it becomes impossible.. The squamous cell lung cancer in many patients tends to spread to other tissues including kidney or bone. Suppose, if it spreads to bones, most of the times, mandible or skull may get affected and in such cases increased density with occurrence of periosteal new bones may be noticed.. Squamous cell lung cancer at times need confirmation from ...
Non‑small cell lung cancer (NSCLC) constitutes the majority of all lung‑cancer cases. Aquaporin 5 (AQP5) may be involved in NSCLC by promoting lung‑cancer initiation and progression. The present study aimed to determine the role of AQP5 in migration and angiogenesis using NSCLC cells and HUVECs. AQPs 1, 3, 4, 5, 8 and 9 were screened in the NSCLC cell line H1299, and the present results showed that AQP5 mRNA was upregulated compared with the other AQP genes. At the protein level, AQP5 was significantly increased in H1299 cells compared with 16HBE cells. AQP5 knockdown in H1299 cells significantly decreased cell migration compared with untransfected cells, as demonstrated by both Transwell and wound closure assays. The present study further investigated H1299 ability to promote HUVEC vascularisation. The supernatants of both transfected and untransfected H1299 cells were used as conditioned medium for HUVECs, and tube formation was measured. The supernatant of AQP5‑downregulated cells ...
In an interview with SurvivorNet, Dr. Ronald Natale discussed current clinical trials testing drug Tagrisso on early stage lung cancer patients. While findings have been historic, there is still controversy surrounding how this drug impacts overall survivor rate.
BackgroundStereotactic body radiotherapy (SBRT) demonstrates excellent local control in early stage lung cancer, however a quarter of patients develop recurrence or distant metastasis. Transforming growth factor-beta (TGF-β) supports metastasis and treatment resistance, and angiote...
TY - JOUR. T1 - Mutational analysis of multiple lung cancers. T2 - Discrimination between primary and metastatic lung cancers by genomic profile. AU - Goto, Taichiro. AU - Hirotsu, Yosuke. AU - Mochizuki, Hitoshi. AU - Nakagomi, Takahiro. AU - Shikata, Daichi. AU - Yokoyama, Yujiro. AU - Oyama, Toshio. AU - Amemiya, Kenji. AU - Okimoto, Kenichiro. AU - Omata, Masao. PY - 2017/1/1. Y1 - 2017/1/1. N2 - In cases of multiple lung cancers, individual tumors may represent either a primary lung cancer or both primary and metastatic lung cancers. Treatment selection varies depending on such features, and this discrimination is critically important in predicting prognosis. The present study was undertaken to determine the efficacy and validity of mutation analysis as a means of determining whether multiple lung cancers are primary or metastatic in nature. The study involved 12 patients who underwent surgery in our department for multiple lung cancers between July 2014 and March 2016. Tumor cells were ...
Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor. Clinical trials have reported its effectiveness in the treatment of brain metastases from non-small cell lung cancer by overcoming the blood-brain barrier. Gefitinib is generally regarded as a relatively safe agent, and several reports have described its efficacy in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and a poor performance status. We herein described two patients with brain metastasis from non-small cell lung cancer who achieved the total regression of metastasis with the administration of gefitinib. A 70-year-old Japanese woman was referred to our hospital with a severe cough. Brain magnetic resonance imaging revealed a metastatic lesion in the left temporal lobe. The tumor was positive for an epidermal growth factor receptor L858R mutation in exon 21 using the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp method. She was treated with 250 mg
The Small Cell Lung Cancer Treatment Market is driven by the launch of premium-priced therapies, including anti-PD-1 and anti-CTLA-4 immunotherapies and targeted agents. The market growth is estimated to occur across the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Japan.. Browse Detailed Toc, Tables, Figures, Charts and Companies Mentioned in Small Cell Lung Cancer Treatment Market ResearchReport at- http://www.absolutereports.com/opportunityanalyzer-small-cell-lung-cancer-sclc-opportunity-analysis-and-forecasts-to-2024-10112598. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor Yervoy will be the first immunotherapy to be introduced in the market. This drug is being developed by Bristol-Myers Squibb and will be launched in 2016 across the seven major markets.. The increase in rates of the disease across the five European markets and Japan, at a CAGR of 1.49% over the forecast period is estimated to further bolster the Small Cell Lung Cancer treatment ...
This phase I trial studies the best dose of radiation therapy in treating patients with locally advanced non-small cell lung cancer that cannot be removed by surgery. Radiation therapy uses high energy x rays to kill tumor cells. Specialized radiation therapy, such as stereotactic body radiation therapy (SBRT), that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. SBRT has been shown to provide excellent results when used in early stage lung cancer, but has not yet been applied to patients with more advanced disease ...
Since 2000, the WHPP Early Lung Cancer Detection (ELCD) Program has provided low-dose chest CT scans to U.S. Department of Energy (DOE) workers, with the primary purpose of detecting lung cancers early. The WHPP ELCD Program serves DOE workers from nine sites in the DOE complex: Idaho National Laboratory (INL); the K-25, Paducah and Portsmouth gaseous diffusion plants (GDPs); the Mound and Fernald closure sites; the Nevada National Security Site (formerly the Nevada Test Site); Oak Ridge National Laboratory; and Y-12. As of September 2015, over 13,000 DOE workers have received low-dose screening CT scans through the ELCD Program; 136 lung cancers have been detected, with the majority (71%) found in early stages.. WHPP participants with an elevated risk of lung cancer based on age, smoking and work history are currently offered annual screening, as well as interim follow-up CT scans, if needed.. A low-dose screening CT scan of the chest uses much less radiation than a standard, full-dose CT scan ...
An increasing number of chromosomal aberrations is being identified in solid tumors providing novel biomarkers for various types of cancer and new insights into the mechanisms of carcinogenesis. We applied next generation sequencing technique to analyze the transcriptome of the non-small cell lung carcinoma (NSCLC) cell line H2228 and discovered a fusion transcript composed of multiple exons of ALK (anaplastic lymphoma receptor tyrosine kinase) and PTPN3 (protein tyrosine phosphatase, nonreceptor Type 3). Detailed analysis of the genomic structure revealed that a portion of genomic region encompassing Exons 10 and 11 of ALK has been translocated into the intronic region between Exons 2 and 3 of PTPN3. The key net result appears to be the null mutation of one allele of PTPN3, a gene with tumor suppressor activity. Consistently, ectopic expression of PTPN3 in NSCLC cell lines led to inhibition of colony formation. Our study confirms the utility of next generation sequencing as a tool for the ...
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
Somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) have recently been described in patients with non-small-cell lung cancer (NSCLC) who achieve radiographic regressions to the EGFR inhibitor gefitinib. One of these mutations, L858R (Leu→Arg), is also found in NSCLC cell line H3255, which is very sensitive to gefitinib treatment. We characterized nine NSCLC cell lines (three isolated from patients with bronchioloalveolar carcinoma and six isolated from patients with adenocarcinoma) for their in vitro sensitivity to gefitinib. Of these, only H3255 (EGFRL858R) and H1666 (EGFRWT) are sensitive to gefitinib with IC50 values of 40 nmol/L and 2 μmol/L, respectively. We examined the effects of gefitinib on H3255 and cell lines containing wild-type EGFR that are either sensitive (H1666) or resistant (A549 and H441) to gefitinib exposure in vitro. Gefitinib treatment (1 μmol/L) leads to significant apoptosis accompanied by increased poly(ADP-ribose) ...
[130 Pages Report] Check for Discount on United States Non Small Cell Lung Cancer Therapeutics Industry 2016 Market Research Report report by QYResearch Group. The United States Non Small Cell Lung Cancer Therapeutics Industry...
Lung cancer remains the most frequent cause of cancer death in both men and women in the world. Surgical resection using lobectomy with mediastinal lymph node dissection or sampling has been a standard of care for operable early stage NSCLC. Several studies have reported high local control and survival using SBRT in stage I NSCLC patients. SBRT is now an accepted treatment for medically inoperable patients with stage I NSCLC and patients with operable stage I lung cancer are entered on clinical protocols. The purpose of this study is to conduct a phase III randomized study to compare CyberKnife SBRT with surgery, the current standard of care for stage I operable NSCLC ...
Doctor answers on Symptoms, Diagnosis, Treatment, and More: Dr. Wright on life chances with non small cell lung cancer: Stage 1 nsclc; surgical resection, appr70%5yrsurv stage2nsclc;surgery apprx. 30-35% 5 yr survival. for topic: Life Chances With Non Small Cell Lung Cancer
Between 1990 and 2011, almost 720,000 people were diagnosed with lung cancer. During this time, the number of male lung cancer diagnoses declined, whereas the number of female lung cancer diagnoses increased. Lung cancer incidence increases sharply after middle age. More than 75% of lung cancers are diagnosed in people over the age of 65. The difference in the trends of lung cancer incidence among men and women is even more pronounced when age is taken into account. The sharp decrease in the incidence of male lung cancer over the past two decades reflects the decline in smoking prevalence among men. However, due to the rise in women who took up smoking after World War II, the incidence among women continues to increase. The difference in smoking prevalence between men and women has given rise to a dramatic change in the male to female lung cancer incidence ratio from 3:1 in 1990 to 3:2 in 2011.. ...
For patients with Stage III non-small cell lung cancer, prophylactic (preventive) radiation therapy to the brain reduces the risk of brain metastases but carries a risk of memory problems and doesnt appear to improve overall survival. These results were published in the Journal of Clinical Oncology.. Lung cancer remains the leading cause of cancer death in the United States. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers.. One of the sites to which NSCLC can spread (metastasize) is the brain. Brain metastases can have a profound effect on survival and quality of life.. Prophylactic cranial irradiation (PCI) refers to the administration of radiation to the brain before brain metastases become apparent. The goal of PCI is the prevention of brain metastases. Previous studies have suggested that PCI can reduce the occurrence of brain metastases, but PCI has not become a part of routine NSCLC care because of concern about side effects and lack of evidence that ...
Objective: Lung cancer is the leading cause of cancer-related mortality worldwide. Disease stage still remains the best prognostic factor for patients with localized non-small cell lung cancer. The TNM staging system, however, does not address the heterogeneity of this disease. Sub-classification and identification of distinct prognostic sub-groups within each stage may allow the optimization of clinical trial design and potentially improve outcome. This is a retrospective pilot study, in which we attempt to identify genomic biomarkers predictive of recurrence in stage I lung cancer by analysing copy number (CN) data obtained by next-generation sequencing. Materials and Methods: Ninety eight patients with stage I NSCLC, who underwent elective radical surgery were identified from a tissue bank of 323 tumour samples. Their demographic and surgical data, including their recurrence status were collected and an extensive database compiled. The cases were split into two cohorts depending on their ...
TY - JOUR. T1 - Inactivation of LLC1 gene in nonsmall cell lung cancer. AU - Hong, Kyeong Man. AU - Yang, Sei Hoon. AU - Chowdhuri, Sinchita Roy. AU - Player, Audrey. AU - Hames, Megan. AU - Fukuoka, Junya. AU - Meerzaman, Daoud. AU - Dracheva, Tatiana. AU - Sun, Zhifu. AU - Yang, Ping. AU - Jen, Jin. PY - 2007/6/1. Y1 - 2007/6/1. N2 - Serial analysis of gene expression studies led us to identify a previously unknown gene, c20orf85, that is present in the normal lung epithelium but absent or downregulated in most primary non-small cell lung cancers and lung cancer cell lines. We named this gene LLC1 for Low in Lung Cancer 1. LLC1 is located on chromosome 20q13.3 and has a 70% GC content in the promoter region. It has 4 exons and encodes a protein containing 137 amino acids. By in situ hybridization, we observed that LLC1 message is localized in normal lung bronchial epithelial cells but absent in 13 of 14 lung adenocarcinoma and 9 out of 10 lung squamous carcinoma samples. Methylation at CpG ...
Non-small cell lung cancer is the most common type of lung cancer. About 85% of lung cancers are non-small cell lung cancers. Squamous cell carcinoma, adenocarcinoma, and large cell carcinoma are all subtypes of non-small cell lung cancer.
Non-small cell lung cancer is the most common type of lung cancer. About 85% of lung cancers are non-small cell lung cancers. Squamous cell carcinoma, adenocarcinoma, and large cell carcinoma are all subtypes of non-small cell lung cancer.
Disorders of cell adhesion are critical steps in cancer progression in which varieties of markers including cadherins are involved in.Btbd7 was found to inhibit E-cadherin expression in MDCK cells and play important roles during branching morphogenesis of embryonic salivary glands and lungs. However its function in malignant tumors is largely unknown. The aim of this study is to investigate the clinicopathological significance and possible function of Btbd7 in non-small cell lung cancer. Immunohistochemistry and Western blotting were used to investigate Btbd7 expression in non-small cell lung cancer and lung tissues. The clinicopathological association and the overall survival was analyzed. In vitro experiments were performed using siRNA to investigate the function of Btbd7 in lung cancer cells. Btbd7 expression was elevated in non-small cell lung cancer tissues compared to normal lung tissues. Increased Btbd7 expression was significantly associated with lymph node metastasis, reduced E-cadherin
The purpose of this study is to find out if adding the study drug, nivolumab, after surgery and chemotherapy will limit lung cancer from growing back in patients with early stage non-small cell lung cancer. Nivolumab is a drug that may turn on the bodys immune system to attack any cancer cells that may remain after surgery.
Metastatic lung cancer survival rate is very low. This kind of lung cancer can prolong life but only for minimal months. It is a stage that involves cancer
TY - JOUR. T1 - Comparison study of quality of life in advanced lung cancer patients on tyrosine kinase inhibitor and platinum doublet chemotherapy. AU - Udupa, K.. AU - Rajendranath, R.. AU - Sagar, T. G.. PY - 2017/1/1. Y1 - 2017/1/1. N2 - INTRODUCTION: Lung cancer is most common cause of cancer death in the world. Most of the patient are diagnosed in the late stages and receive only palliative treatment. The main objective of the palliative chemotherapy is to improve survival as well as the quality of life (QOL). QOL is the most neglected dimension of cancer care in developing countries like India. Palliative chemotherapeutic agent which has minimum toxicity and prolongs the survival of metastatic cancer patients is the need of the day. MATERIALS AND METHODS: In this study, 43 metastatic adenocarcinoma of lung patients of South Indian origin were enrolled. Twenty patients out of this 43 were epidermal growth factor receptor (EGFR) mutation positive and were started on tyrosine kinase ...
Data & statistics on Lung cancer mortality by ethnic group age group and sex: Lung cancer mortality, by ethnic group, age group and sex, 2011, Lung Cancer Mortality Rates by Sex and Ethnicity 1987-1995 Age-adjusted lung cancer mortality rates by sex and ethnicity for the combined period 1990 through 1995, along with their 95% confidence intervals and the rate ratios of each group compared to White rates, are shown in Table 21. (See also Figures 6 and 7, pp. 28-29) Table 21: Lung Cancer Mortality Rates and Rate Ratios by Ethnicity and Sex, ..., That the lung cancer mortality rates in North Denver women were higher than rates in the remainder of the Metro area in all race/ethnicity groups; the differences were statistically significant for all races combined, and white non-Hispanics. For males, lung cancer mortality rates in North Denver were higher than other Metro area rates for all races combined, white non-Hispanics, and Hispanics, but ......
TY - JOUR. T1 - XPC mRNA level may predict relapse in never-smokers with non-small cell lung cancers. AU - Yeh, Kun Tu. AU - Wu, Yi Hui. AU - Lee, Ming Ching. AU - Wang, Lee. AU - Li, Chien Te. AU - Chen, Chih Yi. AU - Lee, Huei. PY - 2012/3. Y1 - 2012/3. N2 - Background. Disease recurrence and distant metastasis are the major causes of death in resected non-small cell lung cancer (NSCLC). The prognostic marker for never-smokers with this disease remains to be identified. To improve patient outcome, establishing an adjacent molecular marker to predict relapse of NSCLC in never-smokers is needed. Methods. Three hundred two lung tumors from NSCLC patients and normal lung tissues from 68 noncancer subjects were enrolled to evaluate XPC (xeroderma pigmentosum group C) mRNA expression by quantitative real-time reverse transcriptase polymerase chain reaction. Receiver operating characteristic curve analysis was used to search for a feasible cutoff point of XPC mRNA levels for predicting ...
Lung cancer remains the major cause of cancer-related mortality worldwide. Non-small cell lung cancer (NSCLC) account for at least 80% of all lung tumors and about 30% of them present with unresectable locally advanced disease at diagnosis (stage IIIA-IIIB) [1]. Until the mid 1980s standard treatment of patients with inoperable locally advanced NSCLC consisted of radiotherapy (RT) alone with a median survival time of 10 months[1]. From data about lung cancer population diagnosed in the second half of 1990s, overall survival at one and two years was estimated of 36% and 12% respectively[2].. Rates at 2 and 5 years of 15% and 5% respectively [3]. In attempts to improve the survival in these patients, chemotherapy was added to external beam irradiation. Several trials have been positive in favour of combined therapy [4-6]. More recently, other clinical trials have shown that, in selected patients (good performance status, age ≤ 75 years and minimal weight loss) concomitant platinum-based ...
Inactivation of the p16 and ESR1 tumor suppressor genes by promoter lesion methylation has been reported in many tumor types, including lung cancer. We examined the blood of 95 non-small cell lung cancer patients (66 cases of adenocarcinoma, 23 of squamous cell carcinoma and 6 of large cell carcinoma) and 30 controls consisting of normal subjects and benign disease patients to determine the methylation ratios of p16 and ESR1 using real-time PCR. For both genes, there was a statistically significant difference in the methylation ratio between non-small cell lung cancer patients and controls (p16; ...
TY - JOUR. T1 - Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma. AU - Improta, Giuseppina. AU - Zupa, Angela. AU - Natalicchio, Maria Iole. AU - Sisinni, Lorenza. AU - Marinaccio, Anna. AU - Bozza, Giovanni. AU - Vita, Giulia. AU - Aieta, Michele. AU - Landriscina, Matteo. PY - 2018/1/31. Y1 - 2018/1/31. N2 - Exons 19-21 EGFR activating mutations are predictive biomarkers of response to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). However, uncommon exon 19 EGFR mutations, due to their low frequency, have an uncertain biological and clinical significance and very little is known about their TKI sensitivity. This study was designed to describe the TKI sensitivity of a small cohort of lung adenocarcinomas bearing uncommon exon 19 mutations and to evaluate in silico the correlation between frame-shift exon 19 mutations and EGFR sequence/structure modification. Among 1168 NSCLCs screened for ...
TY - JOUR. T1 - Predictors of primary lung cancer in a solitary pulmonary lesion after a previous malignancy. AU - Nakadate, Akie. AU - Nakadate, Masashi. AU - Sato, Yasunori. AU - Nakagawa, Tassei. AU - Yoshida, Katsuya. AU - Suzuki, Yoshio. AU - Yoshida, Yukihiro. PY - 2017/12/1. Y1 - 2017/12/1. N2 - Objective: A solitary pulmonary lesion in patients with a history of malignancy may be either primary lung cancer or a metastatic lung tumor or benign nodule. We retrospectively examined the preoperative predictive factors for determining the type of pathology. Methods: We used an exact logistic regression analysis to identify radiological and clinical predictors of primary lung cancer. The study included 187 patients who underwent pulmonary resection for a solitary pulmonary lesion and had received previous treatment for a malignancy. Results: There were 107 patients with primary lung cancer, 74 with metastatic lung tumors, and 6 with benign lesions. The previous malignancy included colorectal ...
All information about the latest scientific publications of the Clínica Universidad de Navarra. Survival of Patients with Stage I Lung Cancer Detected on CT Screening
Effects of interferons and tumour necrosis factor-a on human lung cancer cell lines and the development of an interferon-resistant lung cancer cell line. ...
1. Torre LA, Siegel RL, Jemal A. Lung Cancer Statistics. Adv Exp Med Biol. 2016;893:1-19 2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7-30 3. Lim SM, Syn NL, Cho BC, Soo RA. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies. Cancer Treat Rev. 2018;65:1-10 4. Yue J, Lv D, Wang C, Li L, Zhao Q, Chen H. et al. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin beta3. Oncogene. 2018;37:4300-12 5. Dragnev K, You M Fau - Wang Y, Wang Y Fau - Lubet R, Lubet R. Lung cancer chemoprevention: difficulties, promise and potential agents?. Expert Opin Investig Drugs. 2013;22:35-47 6. Li Q, Zhang D, Chen X, He L, Li T, Xu X. et al. Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer. Scientific reports. 2015;5:16082 7. Tang J, Guo F, Du Y, Liu X, Qin Q, Liu X. et al. Continuous ...
Although the following paper was published already 7 months ago (January 2010, in the British Medical Journal), and is no longer new news, I strongly feel that the information needs to be reinforced.. The authors conducted a review of 10 high-quality studies that evaluated the potential influence on survival in patients with lung cancer who quit smoking after their diagnosis. Most of the studies (9 out of 10) looked only at the effects of smoking in cessation in patients with early stage lung cancers.. What they found was quite remarkable: survival rates doubled among those patients who quit smoking after their diagnosis! In patients with early stage, non-small cell lung cancers, the 5-year survival rates were 33% vs. 70%, in smokers and non-smokers, respectively. In patients with limited stage small cell lung cancer, the 5-year survival rates were 29% vs. 63%, in smokers and non-smokers, respectively.. The authors concluded from their analysis that the doubling of survival was most likely due ...
During this years AACR Annual Meeting we spoke to Dr. Delphine Lissa and Dr. Ana Robles from the National Cancer Institute to learn more about the teams most recent study on the use of two specific biomarkers for risk stratification of stage I lung cancer patients.
San Antonio (TX), Bolton (MA). As originally published in International Clinical Trials, May 2015 - View PDF. In the fight against non-small cell lung cancer, all eyes have been on computed tomography imaging to aid early detection. But advances in the field are leading the oncology and radiology communities to consider novel measurement parameters and techniques to better assess tumour response.. Lung Cancer: Lung cancer is the leading cause of cancer death across the globe, claiming more lives than the next three most common cancers combined (colon, breast and pancreatic). In 2012, the estimate for new cases of lung cancer reached 226,160, with 164,770 deaths accounting for 27% of all cancer deaths. The five-year survival rate is low at 16%, often due to most patients having advanced disease at the time of presentation.. Non-small cell lung cancer (NSCLC) accounts for some 85% of lung cancer diagnoses. Fortunately for this subset of patients, surgery can often be curative, but only if ...
TY - JOUR. T1 - Circulating plasma DNA in non-small cell lung cancer patients is not influenced by inflammatory pulmonary conditions. AU - van der Drift, M.A.. AU - Hol, B.E.A.. AU - Klaassen, C.D.. AU - Prinsen, C.. AU - van Aarssen, Y.A.W.G.. AU - Dekhuijzen, P.N.R.. AU - van der Stappen, J.W.J.. AU - Thunnissen, F.B.J.M.. PY - 2009. Y1 - 2009. M3 - Article. VL - 4. SP - S903-S903. JO - Journal of Thoracic Oncology. JF - Journal of Thoracic Oncology. SN - 1556-0864. IS - 9. ER - ...
Objective: To report the median survival time in a contemporary cohort of dogs with primary lung tumors and intrathoracic nodal metastasis.Design: Retrospective Case Series.Animals (or sample): Dogs with primary lung tumors treated with lung lobectomy and lymph node biopsy.Procedures: The medical record database at Colorado State University was queried for dogs with primary lung tumors from January 1, 2005 to December 31, 2017. Patients were identified for inclusion if they had lung lobectomy and an intrathoracic lymph node biopsy performed. The median survival time (MST) for lymph node positive (LN+) and negative dogs (LN-) was calculated as well as the MST in dogs that did or did not receive adjuvant chemotherapy. Differences were compared between groups with significance set at p Results: The MST in LN+ dogs (n = 11) was 167 days which was not statistically different from LN- dogs (n = 29) at 456 days (p = 0.2407). No significant difference in the MST in LN+ dogs was identified between dogs that
TY - JOUR. T1 - MicroRNAs in non-small cell lung cancer. T2 - Gene regulation, impact on cancer cellular processes, and therapeutic potential. AU - Petrek, Hannah. AU - Yu, Ai Ming. PY - 2019/12/1. Y1 - 2019/12/1. N2 - Lung cancer remains the most lethal cancer among men and women in the United States and worldwide. The majority of lung cancer cases are classified as non-small cell lung cancer (NSCLC). Developing new therapeutics on the basis of better understanding of NSCLC biology is critical to improve the treatment of NSCLC. MicroRNAs (miRNAs or miRs) are a superfamily of genome-derived, small noncoding RNAs that govern posttranscriptional gene expression in cells. Functional miRNAs are commonly dysregulated in NSCLC, caused by genomic deletion, methylation, or altered processing, which may lead to the changes of many cancer-related pathways and processes, such as growth and death signaling, metabolism, angiogenesis, cell cycle, and epithelial to mesenchymal transition, as well as ...
Hello - My husband is a 33 year old non smoker and has been diagnosed with non small cell lung cancer in March 2012. He was not feeling well for a few months with a dry cough which turned into flu like symptoms. His PCP prescribed numerous meds and thought he had pneumonia. He came home from work one night and was complaining of blurred vision, fever & chills. I took him to the ER and he was admitted. The following morning he met with a pulmonary doctor who performed a bronchoscopy. From here, we were told that my husband had mold in his lungs. He was placed on medication for this. A month later he had a follow up with his doctor who informed him that mold was NOT in his lungs. My husband was sent for a CT scan & was told the following morning that he had a collapsed right lung. A chest tube was put in immediately & a right lung biopsy was done. This came back as cancer. We went for a second opinion & cancer was confirmed. My husband underwent a few surgical procedures & has 2 tumors in his ...
Effect of Ape1/Ref-1 on injury caused by stereotactic ablative radiotherapy in the treatment of early stage non-small cell lung cancer, Lei Han, Renzhi Yu, Xin Ni, Zenglei Zhang
Lung cancer is the leading cause of cancer-related mortality. Therapies against non-small cell lung cancer (NSCLC) are particularly needed, as this type of cancer is relatively insensitive to chemotherapy and radiation therapy. We recently identified GGTI compounds that are designed to block geranylgeranylation and membrane association of signaling proteins including the Rho family G-proteins. One of the GGTIs is P61A6 which inhibits proliferation of human cancer cells, causes cell cycle effects with G1 accumulation and exhibits tumor-suppressing effects with human pancreatic cancer xenografts. In this paper, we investigated effects of P61A6 on non-small cell lung cancer (NSCLC) cells in vitro and in vivo. Three non-small cell lung cancer cell lines were used to test the ability of P61A6 to inhibit cell proliferation. Further characterization involved analyses of geranylgeranylation, membrane association and activation of RhoA, and anchorage-dependent and -independent growth, as well as cell cycle
Management of local recurrences and regional failure in early stage non-small cell lung cancer after stereotactic body radiation therapy
TY - JOUR. T1 - Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma. AU - Gjerstorff, Morten F. AU - Pøhl, Mette. AU - Olsen, Karen E. AU - Ditzel, Henrik J. PY - 2013. Y1 - 2013. N2 - The unique expression pattern and immunogenic properties of cancer/testis antigens make them ideal targets for immunotherapy of cancer. The MAGE-A3 cancer/testis antigen is frequently expressed in non-small cell lung cancer (NSCLC) and vaccination with MAGE-A3 in patients with MAGE-A3-positive NSCLC has shown promising results. However, little is known about the expression of other cancer/testis antigens in NSCLC. In the present study the expression of cancer/testis antigens GAGE, NY-ESO-1 and SP17 was investigated in patients with completely resected, early stage, primary NSCLC.. AB - The unique expression pattern and immunogenic properties of cancer/testis antigens make them ideal targets for immunotherapy of cancer. The MAGE-A3 cancer/testis antigen ...
TY - JOUR. T1 - Paclitaxel by either 1-hour or 24-hour infusion in combination with carboplatin in advanced non-small cell lung cancer. T2 - Preliminary results comparing sequential phase II trials. AU - DeVore, R. F.. AU - Jagasia, M.. AU - Johnson, D. H.. PY - 1997/10/22. Y1 - 1997/10/22. N2 - Our group previously described the activity of carboplatin plus paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) (given as a 24-hour infusion) in 51 patients with advanced non-small cell lung cancer. To facilitate outpatient administration, the regimen was modified to infuse paclitaxel over 1 hour. Between February 1995 and August 1996, 63 patients with advanced non-small cell lung cancer were accrued by the Vanderbilt Cancer Center and its affiliate network. The first four patients received paclitaxel 175 mg/ml2; all subsequent patients received paclitaxel 200 mg/m2. The carboplatin dose was determined using the Calvert formula, with a target area under the concentration-time curve of 6. ...
TY - JOUR. T1 - Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer. T2 - The eastern cooperative oncology group results. AU - Chang, A. Y.. AU - Kim, K.. AU - Glick, J.. AU - Anderson, T.. AU - Karp, D.. AU - Johnson, D.. PY - 1993/3/3. Y1 - 1993/3/3. N2 - Background: Patients with metastatic (stage IV) non-small-cell lung cancer usually have a poor prognosis and disease refractory to chemotherapy. Three new agents-taxol, merbarone, and piroxantrone-have shown promising antitumor treatment in vitro and in animals. Taxol is an antimicrotubular agent that interferes with mitosis during cell division. Merbarone, a conjugate of thiobarbituric acid and aniline, is a topoisomerase II inhibitor, which thus inhibits DNA synthesis and tumor growth. Piroxantrone, an anthracenedione derivative, is a DNA intercalating agent that has shown potent antitumor activity in animal studies. Purpose: Our randomized phase II study was designed to evaluate the efficacy and ...
RATIONALE: Sorafenib and erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Giving sorafenib together with erlotinib may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving sorafenib together with erlotinib works in treating patients with stage IIIB or stage IV non-small cell lung cancer that has not responded to chemotherapy.
TY - JOUR. T1 - Use of MicroRNA expression levels to predict outcomes in resected stage i non-small cell lung cancer. AU - Duncavage, Eric. AU - Goodgame, Boone. AU - Sezhiyan, Ananth. AU - Govindan, Ramaswamy. AU - Pfeifer, John. PY - 2010/11. Y1 - 2010/11. N2 - Background: Despite undergoing curative resection, nearly a third of patients with stage I non-small cell lung cancer (NSCLC) die of recurrent disease. There are no reliable clinical or molecular predictors of relapse in patients with resected stage I NSCLC. Identifying patients at risk for relapse after surgical resection is one of the important challenges today. MicroRNAs (miRNAs) regulate hundreds of genes central to maintaining a cancer phenotype. Methods: In an exploratory study, we determined whether expression of six miRNAs (let-7a, miR-7, miR-21, miR-155, miR-210, and miR-221) previously reported to correlate with invasiveness or outcome in various human malignancies were associated with tumor recurrence in patients with ...
Ionic channel activity is involved in fundamental cellular behaviour and participates in cancerous features such as proliferation, migration and invasion which in turn contribute to the metastatic process. In this study, we investigated the expression and role of voltage-gated sodium channels in non-small-cell lung cancer cell lines. Functional voltage-gated sodium channels expression was investigated in normal and non-small-cell lung cancer cell lines. The measurement, in patch-clamp conditions, of tetrodotoxin-inhibitable sodium currents indicated that the strongly metastatic cancerous cell lines H23, H460 and Calu-1 possess functional sodium channels while normal and weakly metastatic cell lines do not. While all the cell lines expressed mRNA for numerous sodium channel isoforms, only H23, H460 and Calu-1 cells had a 250 kDa protein corresponding to the functional channel. The other cell lines also had another protein of 230 kDa which is not addressed to the membrane and might act as a dominant
PURPOSE OF REVIEW: The first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib and erlotinib, are effective as first-line treatment of advanced nonsmall cell lung cancer (NSCLC) harboring activating EGFR mutations (deletions in exon 19 and exon 21 L858R mutation). EGFR T790 M resistance mutation (EGFR T790 M) ultimately emerged in most of these patients. The second and third-generation EGFR-TKIs were designed to have more potent inhibition of EGFR and to overcome EGFR T790 M. This review describes the recent developments of these novel EGFR-TKIs.. RECENT FINDINGS: The second-generation EGFR-TKIs, afatinib and dacomitinib, irreversibly bind to the tyrosine kinase of EGFR and other ErbB-family members. Afatinib has been approved as first-line treatment of advanced NSCLC harboring activating EGFR mutations. Dacomitinib is under development. Third-generation EGFR-TKIs, AZD9291, CO-1686, and HM61713, inhibit both EGFR activating and resistance mutations, ...
Nieder, Carsten; Andratschke, Nicolaus H; Guckenberger, Matthias (2015). A pooled analysis of stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small cell lung cancer: is failure to recruit patients into randomized trials also an answer to the research question? Annals of Translational Medicine, 3(11):148-151. ...
This phase II trial is studying how well erlotinib works in treating patients with advanced primary non-small cell lung cancer. Erlotinib may stop the g
Objective: To explore the effect of Ape1/Ref-1 on injury caused by stereotactic ablative radiotherapy in the treatment of early stage non-small cell l..
BioAssay record AID 81529 submitted by ChEMBL: Cytotoxicity against NCI tumor panel, HOP-92 non small-cell lung cancer cell line.
This phase II trial is studying how well saracatinib works in treating patients with recurrent, stage IIIB or stage IV non-small cell lung cancer previo
SOTIO presented new statistically and clinically significant results from its Phase I/II clinical trial evaluating DCVAC/LuCa, an active cellular immunotherapy product, in patients with stage IV non-small cell lung cancer. The final analysis of the data confirmed the promising clinical efficacy of DCVAC/LuCa.
Abstract: ABSTRACT Although many mouse models of lung adenocarcinoma exist, there is no mouse lung squamous cell carcinoma model that has been validated for use in preclinical lung cancer chemoprevention studies. Since most clinical chemoprevention trials of lung cancer are performed in subjects with bronchial dysplasia, development of a lung squamous cell carcinoma mouse model becomes one of the highest priorities. We have shown that lung squamous cell carcinomas can be induced chemically in several strains of mice (Wang et al. 2004) and that green tea polyphenols exhibit a significant efficacy against the development of lung squamous cell carcinomas (preliminary data section). In this proposal, we will use a standardized green tea preparation called Polyphenon E (PE) and its major component, EGCG. The overall objective of this proposal is to determine the efficacy of green tea polyphenols in a mouse lung squamous cell carcinoma model and to determine the molecular mechanism that underlies the ...
TY - JOUR. T1 - Inhibitory effect of dihydroaustrasulfone alcohol on the migration of human non-small cell lung carcinoma A549 cells and the antitumor effect on a Lewis lung carcinoma-bearing tumor model in C57BL/6J mice. AU - Chen, Shuo Chueh. AU - Chien, Yi Chung. AU - Pan, Chun Hsu. AU - Sheu, Jyh Horng. AU - Chen, Chih Yi. AU - Wu, Chieh Hsi. PY - 2014/1. Y1 - 2014/1. N2 - There are many major causes of cancer death, including metastasis of cancer. Dihydroaustrasulfone alcohol, which is isolated from marine coral, has shown antioxidant activity, but has not been reported to have an anti-cancer effect. We first discovered that dihydroaustrasulfone alcohol provided a concentration-dependent inhibitory effect on the migration and motility of human non-small cell lung carcinoma (NSCLC) A549 cells by trans-well and wound healing assays. The results of a zymography assay and Western blot showed that dihydroaustrasulfone alcohol suppressed the activities and protein expression of matrix ...
TY - JOUR. T1 - Amurubicinol-induced eotaxin-3 expression in human NCI-H69 small cell lung carcinoma cells. AU - Niiya, Masami. AU - Niiya, Kenji. AU - Shibakura, Misako. AU - Asaumi, Noboru. AU - Yoshida, Chikamasa. AU - Tanimoto, Mitsune. PY - 2006/3. Y1 - 2006/3. N2 - We previously demonstrated the doxorubicin-induced expression of urokinase-type plasminogen activator (uPA), interleukin-8 (IL-8), monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor-α in human RCK8 lymphoma cells and NCI-H69 small cell lung carcinoma cells in which reactive oxygen species might be involved. Amurubicin hydrochloride (AMR), a novel derivative drug of doxorubicin, was recently introduced to clinical practice for treatment of lung cancer in Japan. Therefore, we investigated the effects of AMR on the expression of uPA and chemokines in NCI-H69 cells. AMR and its active form, amurubicinol hydrochloride (AMROH), both induced the expression of uPA, IL-8 and MCP-1 in H69 cells in a dose-dependent ...
TY - JOUR. T1 - Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations. T2 - The okayama lung cancer study group trial 1001. AU - Ichihara, Eiki. AU - Hotta, Katsuyuki. AU - Nogami, Naoyuki. AU - Kuyama, Shoichi. AU - Kishino, Daizo. AU - Fujii, Masanori. AU - Kozuki, Toshiyuki. AU - Tabata, Masahiro. AU - Harada, Daijiro. AU - Chikamori, Kenichi. AU - Aoe, Keisuke. AU - Ueoka, Hiroshi. AU - Hosokawa, Shinobu. AU - Bessho, Akihiro. AU - Hisamoto-Sato, Akiko. AU - Kubo, Toshio. AU - Oze, Isao. AU - Takigawa, Nagio. AU - Tanimoto, Mitsune. AU - Kiura, Katsuyuki. PY - 2015/3/30. Y1 - 2015/3/30. N2 - Purpose: Whether bevacizumab enhances the effect of the epidermal growth factor receptor (EGFR) inhibitor gefitinib on EGFR mutant non-small cell lung cancers (NSCLCs) remains unknown. We conducted a phase II trial to investigate the efficacy and safety of gefitinib when combined with bevacizumab as ...
Excerpt:. Patients with advanced non-small-cell lung cancer survive four months longer with fewer side effects on an immunotherapy drug called atezolizumab compared to chemotherapy, according to a phase 3 clinical trial published in The Lancet.. The trial enrolled 1225 advanced non-small-cell lung cancer patients who have no more treatment options, but this study used an early analysis of the first 850 patients from the trial. Half of the group were given atezolizumab and the other half were given docetaxel chemotherapy, which is the standard treatment for advanced non-small-cell lung cancer.. Patients given atezolizumab - a drug that blocks the programmed death ligand 1 (PD-L1) protein - survived for an average of 13.8 months, compared with 9.6 months for those on chemotherapy.. Go to full article.. ...
This study compares administration schedules of experimental MPDL3280A (antibody- a protein produced by the bodys immune system) and stereotactic ablative radiotherapy in treating patients with lung cancer. MPDL3280A, may block tumor growth in different ways by targeting certain cells. Stereotactic ablative radiotherapy, is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue. Giving MPDL3280A with stereotactic ablative radiotherapy may be a better treatment for lung cancer. However, it is not yet known what the best administration schedule is for these treatments. ...
Tumour angiogenesis is an important factor for tumour growth and metastasis. Although some recent reports suggest that microvessel counts in non-small cell lung cancer are related to a poor disease outcome, the results were not conclusive and were not compared with other molecular prognostic markers. In the present study, the vascular grade was assessed in 107 (T1,2-N0,1) operable non-small cell lung carcinomas, using the JC70 monoclonal antibody to CD31. Three vascular grades were defined with appraisal by eye and by Chalkley counting: high (Chalkley score 7-12), medium (5-6), and low (2-4). There was a significant correlation between eye appraisal and Chalkley counting (P | 0.0001). Vascular grade was not related to histology, grade, proliferation index (Ki67), or EGFR or p53 expression. Tumours from younger patients had a higher grade of angiogenesis (P = 0.05). Apart from the vascular grade, none of the other factors examined was statistically related to lymph node metastasis (P | 0.0001). A
A specific, acquired chromosomal abnormality (deletion 3p) has been found in at least one chromosome 3 in 100 percent of the metaphases in 12 of 12 cell lines cultured from human small-cell lung cancer tissue and in 2-day tumor culture specimens from three patients. Analysis of the shortest region of overlap shows the deletion to be 3p(14-23). This specific change was not seen in five of five lung cancer cell lines other than small-cell lung cancer or in two lymphoblastoid lines cultured from cells of small-cell lung cancer patients whose tumors had the 3p deletion. ...
Chapter 107: Neoplasms of the lung. (编) Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscalzo J. Harrison's Principles ... 非小細胞癌(NSCLC)可粗分為三大類:肺腺癌、鱗狀上皮癌(英语:squamous-cell lung carcinoma),和大細胞癌(英语:large-cell lung carcinoma)[1]。 ... 肺癌(英語:Lung cancer[7])是惡性的肺部肿瘤,肇因於肺部組織细胞不受控制地生長(英语:cell growth)[10]。如不治疗,肿瘤细胞會转移至鄰
Usman M, Moore W, Talati R, Watkins K, Bilfinger TV (June 2012). "Irreversible electroporation of lung neoplasm: a case series ... The trial included patients with primary and secondary lung malignancies and preserved lung function. The expected ... In a prospective, single-arm, multi-center, phase II clinical trial, the safety and efficacy of IRE on lung cancers were ... A major obstacle of IRE in the lung is the difficulty in positioning the electrodes; placing the probes in parallel alignment ...
These were cancers of the brain, lung, bowel, breast, and bladder, and other neoplasms. Not only are benzodiazepines associated ...
"Lung folding simulating peripheral pulmonary neoplasm (Blesovsky's syndrome)". Thorax. 35 (12): 936-940. doi:10.1136/thx.35.12. ... folded lung or Blesovsky syndrome), an outer portion of the lung slowly collapses as a result of scarring and shrinkage of the ... findings can include lung opacification and/or loss of lung volume. Post-surgical atelectasis will be bibasal in pattern. Chest ... It is often called a collapsed lung, although that term may also refer to pneumothorax. It is a very common finding in chest x- ...
Tang VK, Vijhani P, Cherian SV, Ambelil M, Estrada-Y-Martin RM (2018). "Primary pulmonary lymphoproliferative neoplasms". Lung ... In rare cases it may not even involve the lung. The lesions in EBV+ LG consist of occasional large, atypical B cells located in ... This LPD occurs primarily in middle aged males (male:female ratio 2:1). EBV+ LG usually (~90% of cases) presents as a lung ... Dalia S, Shao H, Sagatys E, Cualing H, Sokol L (October 2014). "Dendritic cell and histiocytic neoplasms: biology, diagnosis, ...
Chapter 107: Neoplasms of the lung, Harrison's Principles of Internal Medicine, 19th, McGraw-Hill (2015). ISBN 978-0-07-180216- ... a b c Lung Carcinoma: Tumors of the Lungs. Merck Manual Professional Edition, Online edition. [2007. augusztus 16-i dátummal az ... Schiller JH, Vidaver RM, Novello S, Brahmer J, Monroe L: Living with a Diagnosis of Lung Cancer. [National Lung Cancer ... 1998). „European Consensus Statement on Lung Cancer: risk factors and prevention. Lung Cancer Panel". CA Cancer J Clin 48 (3), ...
General etiologies include infections, interstitial lung diseases, pulmonary edema, pulmonary hemorrhage, and neoplasm. A ... GGOs can be seen in normal lungs. Upon expiration there is less air in the lungs, leading to a relative increase in density of ... Although it can sometimes be seen in normal lungs, common pathologic causes include infections, interstitial lung disease, and ... When a substance other than air fills an area of the lung it increases that area's density. On both x-ray and CT, this appears ...
"Lung atelectasis". Radiopaedia. Retrieved 20 February 2017.. *^ "Lung folding simulating peripheral pulmonary neoplasm ( ... In rounded atelectasis (Folded lung or Blesovsky syndrome[10]), an outer portion of the lung slowly collapses as a result of ... findings can include lung opacification and/or loss of lung volume. Post-surgical atelectasis will be bibasal in pattern. Chest ... It may affect part or all of a lung.[1] It is usually unilateral. It is a condition where the alveoli are deflated down to ...
A number of disorders have been mapped in the vicinity of this gene, most notably lung neoplasms. GRCh38: Ensembl release 89: ...
Tobacco smoke causes increased exogenous DNA damage, and these DNA damages are the likely cause of lung cancer due to smoking.[ ... ICD-10 classifies neoplasms into four main groups: benign neoplasms, in situ neoplasms, malignant neoplasms, and neoplasms of ... The term 'neoplasm' is a synonym of "tumor". 'Neoplasia' denotes the process of the formation of neoplasms/tumors, the process ... "II Neoplasms". World Health Organization. Retrieved 19 June 2014.. *^ a b Abrams, Gerald. "Neoplasia I". Retrieved 23 January ...
The cancers included cancer of the brain, lung, bowel, breast, and bladder, and other neoplasms. It has been hypothesised[who ...
Other side effects may include liver disease, lung disease, lymphoma, and severe skin rashes. People on long-term treatment ... and trophoblastic neoplasms. It is used as a disease-modifying treatment for some autoimmune diseases, including rheumatoid ... It is effective for the treatment of a number of cancers, including breast, head and neck, leukemia, lymphoma, lung, ... Types of cancers it is used for include breast cancer, leukemia, lung cancer, lymphoma, gestational trophoblastic disease, and ...
The three-story facility houses outpatient space for evaluation and treatment of solid tumor neoplasms including: lung, head ... Markey patients' have a five-year survival rate in ovarian, lung, brain, prostate, and Stage IV colorectal cancer higher than ...
... lung, pancreas, and colon neoplasms. PELP1 signaling contributes to hormonal therapy resistance. Altered localization of PLP1 ... AR, PELP1 and Src form constitutive complexes in prostate neoplasms model cells that exhibit androgen independence. Cytoplasmic ... and leucine-rich protein PELP1 in non-small cell lung cancer". Biomedicine & Pharmacotherapy. 73: 97-101. doi:10.1016/j.biopha. ...
A study of 93 patients with incurable neoplasms". J Natl Med Assoc. 43 (4): 211-240. PMC 2616951. PMID 14850976.. ... It is effective for the treatment of a number of cancers, including: breast, head and neck, leukemia, lymphoma, lung, ... lung disease, lymphoma, and severe skin rashes.[1] People on long-term treatment should be regularly checked for side effects.[ ... lung cancer, lymphoma, and osteosarcoma.[1] Types of autoimmune diseases it is used for include psoriasis, rheumatoid arthritis ...
... is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: an immunohistochemical ... G1 and G2 neuroendocrine neoplasms are called neuroendocrine tumors (NETs) - formerly called carcinoid tumours. G3 neoplasms ... small-cell lung cancer (SCLC) large cell neuroendocrine carcinoma of the lung (LCNEC) Extrapulmonary small cell carcinomas ( ... Although there are many kinds of NETs, they are treated as a group of tissue because the cells of these neoplasms share common ...
... is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: an immunohistochemical ... This gene is a sensitive marker for neuroendocrine differentiation of human lung tumors. INSM1 has been shown to interact with ...
... and other neoplasms (e.g., lung cancer, lymphoma, and leukemia). Diet may also modulate risk. For example, among immigrants in ... chronic lung disease, malnutrition, and alcoholism. A person's genetics also play a role. People with silicosis have an ...
... malignant neoplasm of bronchus or lung (4.6%), Acute myocardial infarction (3%), pneumonia (2.2%), exposure to unspecified ... malignant neoplasm of pancreas (1.1%), malignant neoplasm of prostate (1.1%), malignant neoplasm of bladder (0.8%). Recently, ... factor, unspecified place (2.1%), acute kidney injury (1.4%), intra-cerebral hemorrhage (1.2%), malignant neoplasm of colon ( ...
Cancer (including neoplasms in the mammalian lung, oral/nasal cavities, thyroid and adrenal glands, and liver, squamous cell ...
Neoplasms of the Lung Chapter 75: Breast Cancer Chapter 76: Upper Gastrointestinal Tract Cancers Chapter 77: Lower ... Lung Abscess Chapter 123: Infective Endocarditis Chapter 124: Infections of the Skin, Muscles, and Soft Tissues Chapter 125: ... Lung Transplantation Part 8: Critical Care Medicine Section 1: Respiratory Critical Care Chapter 293: Approach to the Patient ... Interstitial Lung Disease Chapter 288: Disorders of the Pleura Chapter 289: Disorders of the Mediastinum Chapter 290: Disorders ...
... and lung neoplasms. A small amount of the rat population was able to clear particulate curium sesquioxide from the lungs, ... "Dose Responses from Inhaled Monodisperse Aerosols of 244Cm203 in the Lung, Liver and Skeleton of F344 Rats and Comparison with ... suggesting that curium sesquioxide is partially soluble in lung fluid. Curium(III) oxide is heavily used in industrial grade- ...
... lung cancer, pediatric neoplasms, stereotactic radiosurgery, radiosensitization, combined modality therapies, altered ... He has run numerous multimodality clinical trials at the national level for both adult and pediatric CNS neoplasms. Current ... Combined modality treatment of tumors of the CNS and thorax, as well as pediatric neoplasms: integrating systemic chemotherapy ...
About 0.5% to 1% of all primary malignant lung tumors are childhood tumors of the lung, making it a rare form of neoplasm. ... Retinoblastoma is a rare form of eye neoplasm (found in the retina) that is mostly found in children, being the most common ... This type of malignant neoplasm mimics pancreatic development at 7 weeks of gestation and tends to afflict, most commonly, ... that resemble the lung at week 10 to 16 of gestation. The symptoms for this disease are non-specific, and radiologic features ...
Horn, L; Lovly, CM; Johnson, DH (2015). "Chapter 107: Neoplasms of the lung". In Kasper, DL; Hauser, SL; Jameson, JL; Fauci, AS ... Lung cancer, also known as lung carcinoma,[7] is a malignant lung tumor characterized by uncontrolled cell growth in tissues of ... This article is about lung carcinomas. For other lung tumors, see Lung tumor. ... Most cancers that start in the lung, known as primary lung cancers, are carcinomas.[12] The two main types are small-cell lung ...
Necrotizing tumors: 8% to 18% are due to neoplasms across all age groups, higher in older people; primary squamous carcinoma of ... Lung abscess is a type of liquefactive necrosis of the lung tissue and formation of cavities (more than 2 cm)[1] containing ... Lung abscess is considered primary (60%[2]) when it results from existing lung parenchymal process and is termed secondary when ... Lower RT/lung disease. (including LRTIs). Bronchial/. obstructive. acute. Acute bronchitis. chronic. COPD Chronic bronchitis. ...
... mental retardation Thymic carcinoma Thymic epithelial tumor Thymic renal anal lung dysplasia Thymoma Thymus neoplasm ... Temtamy-Shalash syndrome TEN Ter Haar-Hamel-Hendricks syndrome Ter Haar syndrome Teratocarcinosarcoma Teratoma Testes neoplasm ... syndrome Tolosa-Hunt syndrome Toluene antenatal infection Tomaculous neuropathy Tome-Brune-Fardeau syndrome Tongue neoplasm ... Trisomy 14 mosaicism Trisomy 2 mosaicism Trisomy 3 mosaicism Trisomy 6 Trisomy Trochlear dysplasia Trophoblastic Neoplasms ( ...
... syndrome Lung agenesis heart defect thumb anomalies Lung cancer Lung herniation congenital defect of sternem Lung neoplasm ... Alphabetical list 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z See also Health Exercise Nutrition Labrador lung ... isolated Lissencephaly Listeria infection Listeriosis Livedoid dermatitis Liver cirrhosis Liver neoplasms Lobar atrophy of ... pulmonary Lymphangiomyomatosis Lymphatic filariasis Lymphatic neoplasm Lymphedema distichiasis Lymphedema hereditary type 1 ...
Metastasis to the lung Lung nodule Horn L, Lovly CM (2018). "Chapter 74: Neoplasms of the lung". In Jameson JL, Fauci AS, ... Sarcomas of the lung. Some rare vascular tumors of the lung Non-lung tumors which may grow into the lungs: Mediastinal tumors ... Lung tumors are neoplastic lung nodules. These include: Primary tumors of the lung/pulmonary system: Bronchial leiomyoma, a ... of the lung Pulmonary carcinoid tumor Pleuropulmonary blastoma Neuroendocrine tumors of the lung Lymphomas of the lung. ...
... neoplasms including sarcomas such as hemangiopericytoma and malignant peripheral nerve sheath tumor in ... Allow organs like arteries and lungs to recoil. Elastic microfibril and elastin. extracellular matrix ...
Intracranial neoplasm, brain tumour. Brain metastasis in the right cerebral hemisphere from lung cancer, shown on magnetic ... Neoplasms will often show as differently colored masses (also referred to as processes) in CT or MRI results. ... The skull bone structure can also be subject to a neoplasm that by its very nature reduces the volume of the intracranial ... "CNS and Miscellaneous Intracranial and Intraspinal Neoplasms" (PDF). SEER Pediatric Monograph. National Cancer Institute. pp. ...
Several severe adverse health effects, such as an increased incidence of cancers, thyroid diseases, CNS neoplasms, and possibly ... lung, colon, and thyroid tissues as the most radiosensitive among women. For example, the FGR 13 has estimated that the ratio ... who were affected by disproportionately high incidences of fatal lung cancer. One problem for Navajo widows and widowers ...
Salivary gland neoplasm. *Sarcoma. *Skin cancer. *Small intestine cancer. *Small-cell carcinoma ...
Hemorrhagic neoplasms are more complex, heterogeneous bleeds often with associated edema. These hemorrhages are related to ... Glioblastomas are the most common primary malignancies to hemorrhage while thyroid, renal cell carcinoma, melanoma, and lung ... of consciousness Hypertension Arteriovenous malformation Aneurysm rupture Cerebral amyloid angiopathy Intracranial neoplasm ...
Legend: → tumor ←, ✱ central pleural effusion, 1 & 3 lungs, 2 spine, 4 ribs, 5 aorta, 6 spleen, 7 & 8 kidneys, 9 liver. ... Malignant tumor, malignant neoplasm. A coronal CT scan showing a malignant mesothelioma. ...
Neoplasms 60% increase in death rate 60% increased death rate from neoplasms. In 1999-2003, neoplasms accounted for 17% of all ... "prized because their lungs were believed to have greater air capacity"[85] Aboriginal prisoners in the Aboriginal-only prison ...
It is a malignant neoplasm and is one of the most treatable and curable cancers, with a survival rate above 95% if discovered ... Stage 3 seminoma is characterized by the presence of metastasis outside the retroperitoneum-the lungs in "good risk" cases or ...
"Deep inspiration breath-hold technique for lung tumors: the potential value of target immobilization and reduced lung density ... Hypopituitarism commonly develops after radiation therapy for sellar and parasellar neoplasms, extrasellar brain tumours, head ... For example: non-melanoma skin cancer, head and neck cancer, breast cancer, non-small cell lung cancer, cervical cancer, anal ... and lung. Unfortunately, IMRT is limited by its need for additional time from experienced medical personnel. This is because ...
It is a feature characteristic of malignant neoplasms, and dysplasia. Certain benign cell types may have pleomorphism, e.g. ... Giant cell carcinoma of the lung. *Nuclear atypia. This article related to pathology is a stub. You can help Wikipedia by ...
The two most common cancers that spread to the eye from another organ are breast cancer and lung cancer. Other less common ... Eye neoplasms can affect all parts of the eye, and can be a benign tumor or a malignant tumor (cancer). Eye cancers can be ... Retrieved from "https://en.wikipedia.org/w/index.php?title=Eye_neoplasm&oldid=895356793" ...
Patients with single organ dysfunction due to sepsis (e.g., lung) and recent surgery (within 30 days before drotrecogin use) ... Known or suspected intracranial neoplasm or mass lesion. *Known hypersensitivity to drotrecogin or any component ...
"Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative ...
... men after lung cancer. In the United Kingdom it is also the second most common cause of cancer death after lung cancer, where ... "Male Genitals - Prostate Neoplasms". Pathology study images. University of Virginia School of Medicine. Archived from the ... 5-LOX can be induced by pro-inflammatory stimuli and is expressed in epithelial cancers including lung, prostate, breast, and ... Further investigation with this substance revealed that it could interfere with the LT receptors in the lung carcinoma [38]. In ...
Brain metastasis in the right cerebral hemisphere from lung cancer shown on T1-weighted magnetic resonance imaging with ... "CNS and Miscellaneous Intracranial and Instraspinal Neoplasms" (PDF). SEER Pediatric Monograph. National Cancer Institute. pp ...
Chronically insufficient intake of folic acid may increase the risk of colorectal, breast, ovarian, pancreas, brain, lung, ... Folate deficiency hinders DNA synthesis and cell division, affecting hematopoietic cells and neoplasms the most because of ...
... tumors are also found in the lungs.. Other sites / metastases[edit]. Metastasis of carcinoid can lead to carcinoid ... cystic neoplasms: Serous microcystic adenoma. *Intraductal papillary mucinous neoplasm. *Mucinous cystic neoplasm ... Lung[edit]. Main article: Typical lung carcinoid tumor. ... Non-small-cell lung carcinoma. *Squamous-cell carcinoma. * ...
ISBN 0-7020-2606-9. Huete-Garin, A.; S.S. Sagel (2005). "Chapter 6: "Mediastinum", Thymic Neoplasm". In J.K.T. Lee; S.S. Sagel ... lung. This article incorporates text in the public domain from the 20th edition of Gray's Anatomy (1918) editor-in-chief, Susan ...
Medical imaging (such as ultrasound or CT scanning) can find invasion of other organs commonly the lung, liver, spleen, lymph ... "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia". Blood. 127 (20): ...
Zhao H, Jin S, Antinore MJ, Lung FD, Fan F, Blanck P, Roller P, Fornace AJ, Zhan Q (July 2000). "The central region of Gadd45 ... Neoplasm: Tumor suppressor genes/proteins and Oncogenes/Proto-oncogenes. Ligand. Growth factors. ...
Large cell lung carcinoma (LCLC) is a heterogeneous group of undifferentiated malignant neoplasms originating from transformed ... Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). NSCLC ... Lung adenocarcinoma[edit]. Main article: Adenocarcinoma of the lung. Adenocarcinoma of the lung is currently the most common ... Historically, adenocarcinoma was more often seen peripherally in the lungs than small cell lung cancer and squamous cell lung ...
There are also reports of hematopoiesis taking place in the lungs. These cases are associated with hypertension in the ... In 2016, the WHO revised their classification of myeloproliferative neoplasms to define Prefibrotic primary myelofibrosis as a ... These mutations are not specific to myelofibrosis, and are linked to other myeloproliferative neoplasms, specifically ... Barosi, Giovanni (2011). "Conventional and Investigational Therapy for Primary Myelofibrosis". Myeloproliferative Neoplasms. pp ...
... interstitial lung disease (e.g., bleomycin) and occasionally secondary neoplasm (e.g., MOPP therapy for Hodgkin's disease). ... Lung cancer. Cyclophosphamide, doxorubicin, vincristine,. CAV. Colorectal cancer. 5-fluorouracil, folinic acid, oxaliplatin. ... Colorectal, lung, ovarian and brain cancer. 3. $6.56 billion. Trastuzumab. Herceptin. Roche. Breast, esophagus and stomach ... Isolated limb perfusion (often used in melanoma),[61] or isolated infusion of chemotherapy into the liver[62] or the lung have ...
Promoter hypermetylation of ATM occurs in 47% of non-small-cell lung cancers. Promoter hypermethylation of MLH1 occurs in 48% ... see malignant neoplasms). Thus, CpG island hyper/hypo-methylation in the promoters of DNA repair genes are likely central to ... Promoter hypermethylation of NEIL1 occurs in 62% of head and neck cancers and in 42% of non-small-cell lung cancers. ... Nikolova T, Christmann M, Kaina B (2009). "FEN1 is overexpressed in testis, lung and brain tumors". Anticancer Res. 29 (7): ...
8560-8580) Complex epithelial neoplasms. Carcinoma In situ[edit]. The term carcinoma in situ (or CIS) is a term for cells that ... Lung adenocarcinoma (never-smokers) 1.7 10,200 Cause of mutations[edit]. The likely major underlying cause of mutations in ... 2004). Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart (PDF). World Health Organization Classification ... Carcinoma of the lung has a more complicated staging system, taking into account a number of size and anatomic variables.[21] ...
... can be used for detecting both acute and chronic changes in the lung parenchyma, that is, the internals of the lungs. ... superior information as compared to CT scans when seeking information about headache to confirm a diagnosis of neoplasm, ... LungsEdit. High-resolution computed tomographs of a normal thorax, taken in the axial, coronal and sagittal planes, ... This ranges from arteries serving the brain to those bringing blood to the lungs, kidneys, arms and legs. An example of this ...
They form a subset of neoplasms. A neoplasm or tumor is a group of cells that have undergone unregulated growth and will often ... "Lung Cancer Screening". U.S. Preventive Services Task Force. 2004. Archived from the original on 4 November 2010.. ... "European Consensus Statement on Lung Cancer: risk factors and prevention. Lung Cancer Panel". Ca. 48 (3): 167-76, discussion ... Evidence is insufficient to recommend for or against screening for skin cancer,[132] oral cancer,[133] lung cancer,[134] or ...
Lung agenesis heart defect thumb anomalies. *Lung herniation congenital defect of sternem ... Lymph node neoplasm. *Lymphadenopathy, angioimmunoblastic with dysproteinemia. *Lymphangiectasies lymphoedema type Hennekam ...
Intracranial neoplasm, brain tumour. Brain metastasis in the right cerebral hemisphere from lung cancer, shown on magnetic ... The skull bone structure can also be subject to a neoplasm that by its very nature reduces the volume of the intracranial ... "CNS and Miscellaneous Intracranial and Intraspinal Neoplasms" (PDF). SEER Pediatric Monograph. National Cancer Institute. pp. ... More generally a neoplasm may cause release of metabolic end products (e.g., free radicals, altered electrolytes, ...
Malik SW, Myers JL, DeRemee RA, Specks U (December 1996). "Lung toxicity associated with cyclophosphamide use. Two distinct ... Bernatsky S, Clarke AE, Suissa S (February 2008). "Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis ... small cell lung cancer, neuroblastoma, and sarcoma.[4] As an immune suppressor it is used in nephrotic syndrome and following ... Myeloproliferative neoplasms, including acute leukemia, non-Hodgkin lymphoma and multiple myeloma, occurred in 5 of 119 ...
Lung NeoplasmsA Phase 2, Randomized, Open-Label Study Of Single Agent CI-1033 In Patients With Advanced Non-Small Cell Lung ... Lung NeoplasmsA Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung ... Lung NeoplasmsValidation of Molecular Diagnostic Thecnologies for Lung Cancer Patients. NCT03220230. * Fortaleza, Caera ... Lung NeoplasmsA Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy ...
Anatomical context of Lung Neoplasms. *The doxorubicin-selected lung cancer cell line H69AR is resistant to many ... Chemical compound and disease context of Lung Neoplasms. *Treatment of non-small-cell lung cancer with cisplatin and ... High impact information on Lung Neoplasms. *Somatic activating mutations in EGFR identify a subset of non-small cell lung ... Gene context of Lung Neoplasms. *The FHIT gene 3p14.2 is abnormal in lung cancer [34]. ...
Mitogenic Effect of Orphan Receptor TR3 and Its Regulation by MEKK1 in Lung Cancer Cells Siva Kumar Kolluri, Nathalie Bruey- ... CUB Domain-Containing Protein 1 Is a Novel Regulator of Anoikis Resistance in Lung Adenocarcinoma Takamasa Uekita, Lin Jia, ... c-Jun N-Terminal Kinase Contributes to Aberrant Retinoid Signaling in Lung Cancer Cells by Phosphorylating and Inducing ...
Smoky Coal Exposure, Genetic Susceptibility, and Lung Cancer in Non-Smoking Women in China. *Lung Neoplasms ... Risk Stratification of Patients Using the Lung Cancer Biomarker Panel in China. *Lung Neoplasms ... TF2- Small Cell Lung Cancer Radio Immunotherapy. *Small Cell Lung Cancer. *CEA-expressing Non Small Cell Lung Carcinoma (NSCLC) ... National Lung Cancer Registry in Men and Women Based on Diagnosis in Algeria. *Oncology & Epidemiology & Lung Cancer ...
Feasibility Study Incorporating Lung Function Imaging Into Radiation Therapy for Lung Cancer Patients. *Lung Neoplasms ... Irreversible Electroporation(IRE) For Lung Neoplasms Accompanied by Respiratory Function Insufficiency. *Lung Neoplasms ... Circulating Tumor DNA in Surgical Lung Cancer Patients. *Lung Neoplasms. Observational. *Shenzhen Gene Health Bio Tech Co., Ltd ... A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer. *Lung Neoplasms ...
"Lung Neoplasms" by people in Harvard Catalyst Profiles by year, and whether "Lung Neoplasms" was a major or minor topic of ... "Lung Neoplasms" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical Subject ... Below are the most recent publications written about "Lung Neoplasms" by people in Profiles. ... Below are MeSH descriptors whose meaning is more general than "Lung Neoplasms". ...
... and malignancy of the lung neoplasm. In most cases... ... The treatment for a lung neoplasm varies depending on the cause ... Perhaps the most important of these is whether the tumor is a benign lung neoplasm or a malignant lung neoplasm. The doctor ... Most often, a lung neoplasm will turn out to be cancerous rather than benign, as around a third of lumps found in the lungs are ... A benign lung neoplasm is much rarer than a cancerous one, and benign neoplasms account for up to five percent of cases where a ...
... resected which developed after segmentectomy of a squamous cell carcinoma of the lung and radiologically mimicked a neoplasm. ...
Lung neoplasms explanation free. What is Lung neoplasms? Meaning of Lung neoplasms medical term. What does Lung neoplasms mean? ... Looking for online definition of Lung neoplasms in the Medical Dictionary? ... lung cancer. (redirected from Lung neoplasms). Also found in: Dictionary, Thesaurus, Encyclopedia. lung. [lung] either of two ... brown lung byssinosis.. lung cancer malignant growths of the lung. Although the exact cause of lung cancer is not known, ...
ICD-10 code D14.3 for Benign neoplasm of bronchus and lung is a medical classification as listed by WHO under the range -Benign ... ICD-10-CM Code for Benign neoplasm of bronchus and lung D14.3 ICD-10 code D14.3 for Benign neoplasm of bronchus and lung is a ... medical classification as listed by WHO under the range - Neoplasms .. Subscribe to Codify and get the code details in a flash. ...
Inicio Endocrinología y Nutrición (English Edition) Panhypopituitarism and lung neoplasm: A case study ... Pituitary metastases from lung cancer is a rare clinical situation and less than 20 cases have been reported in the last 5 ... A chest X-ray was performed and revealed a mass in the lower lobe of the right lung. Subsequent bronchoscopy confirmed ... Its frequency is followed by that of lung cancer. Prostate, renal cell and gastrointestinal cancers, as well as lymphoma, ...
Lung - pathology Lung Neoplasms - epidemiology - etiology - pathology Middle Aged Mining Occupational Diseases - epidemiology ... In order to prevent such a late diagnostics all the miners should be referred to the group of risk on lung cancer. ... Clinical and morphologic characteristics of lung cancer in miners of Krivoy Rog iron-ore region and of uranium mines of Zhovti ... In all the cases lung cancer was morphologically proved and classified as squamous. Rapid progression of the disease and late ...
... many pa-tients diagnosed with primary lung cancer will not be surgical candidates. Percutaneous image-guided ... ... Although lung cancer has a high mortality rate, ... especially in the lung. A study in the porcine lung showed ... Current and future applications of percutaneous radiofrequency ablation in the treatment of lung neoplasms. By Michael D. ... Current and future applications of percutaneous radiofrequency ablation in the treatment of lung neoplasms. Appl Radiol. ...
HEPATIC NEOPLASM , Lung Neoplasm , Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors ...
Gastrointestinal Neoplasm , Bronchial Neoplasm , Lung Cancer , Breast Cancer , Bridge: Proactive Psychiatry Consultation and ... Lung Neoplasm , Bipolar Disorder , head and neck cancer , Schizophrenia , Severe Major Depression , ...
These can occur in the lung (1-5% of all lung tumours). Neuroendocrine neoplasm of low malignant potential - most bronchial ... 1. Small cell lung cancer (SCLC) (13%). 2. Non-small cell lung cancer (NSCLC). - SCC (20%). - Adenocarcinoma (40%). - Large ... In lung cancer this is because of the path over the apex of the lung ... and are most commonly found around the hilium of the lung (ex. adenocarcinoma). Regardless of subtype, all lung cancers tend to ...
Home > 2015 ICD-9-CM Diagnosis Codes > Neoplasms 140-239 > Benign Neoplasms 210-229 > Benign neoplasm of respiratory and ... 2015/16 ICD-10-CM D14.30 Benign neoplasm of unspecified bronchus and lung ...
... report of a case presenting with lung and central nervous system involvement and review of the literature.(Case study) by The ... general Central nervous system diseases Case studies Diagnosis Dendritic cells Diseases Lung diseases ... MLA style: "Blastic plasmacytoid dendritic cell neoplasm: report of a case presenting with lung and central nervous system ... APA style: Blastic plasmacytoid dendritic cell neoplasm: report of a case presenting with lung and central nervous system ...
Malignant Neoplasm Of Respiratory And Intrathoracic Organs 160-165 > Malignant neoplasm of trachea bronchus and lung 162- ... T4: Lung tumor of any size with a malignant pleural effusion. *T4: Lung tumor of any size with separate tumor nodule in same ... 2015/16 ICD-10-CM C34.90 Malignant neoplasm of unspecified part of unspecified bronchus or lung ... Squamous cell carcinoma, right lung. *T3: Lung tumor of any size in the main bronchus < 2 cm distal to the carina but without ...
KEY WORDS: medicinal mushrooms, Agaricus brasiliensis, carcinogenesis tests, drug therapy, inflammation, neoplasms, lung ... NNK treatment induced pulmonary inflammation, but not lung cancer, in the rats. The lungs of animals treated with NNK showed a ... The effects of orally administered aqueous A. brasiliensis extract (14.3- and 42.9-mg doses) on parenchymal lung damage induced ...
Lung Diseases, Obstructive Subject Neoplasms Remove constraint Subject: Neoplasms ... You searched for: Genre Official reports Remove constraint Genre: Official reports Subject Lung Diseases, Obstructive Remove ... 6. The Health Consequences of Smoking: Cancer and Chronic Lung Disease in the Workplace: A Report of the Surgeon General ...
... for lung neuroendocrine neoplasm, of which 10 are open and 4 are completed or closed. Of the trials that contain lung ... Lung neuroendocrine neoplasms most frequently harbor alterations in TP53, RB1, KMT2D, CREBBP, and NOTCH1 [2]. ... Drugs Being Investigated in Lung Neuroendocrine Neoplasm Trials by Recruiting Status. ... SSTR2, SSTR1, and SSTR3 are the most frequent gene inclusion criteria for lung neuroendocrine neoplasm clinical trials [3]. ...
C34.10 Malignant neoplasm of upper lobe, unspecified bronchus or lung C34.11 Malignant neoplasm of upper lobe, right bronchus ... C34.30 Malignant neoplasm of lower lobe, unspecified bronchus or lung C34.31 Malignant neoplasm of lower lobe, right bronchus ... C34.32 Malignant neoplasm of lower lobe, left bronchus or lung C34.8 Malignant neoplasm of overlapping sites of bronchus and ... C34.81 Malignant neoplasm of overlapping sites of right bronchus and lung C34.82 Malignant neoplasm of overlapping sites of ...
C34.91 Malignant neoplasm of unspecified part of right bronchus or lung C34.92 Malignant neoplasm of unspecified part of left ... Malignant neoplasm of bronchus and lung. 2016 2017 2018 Non-Billable/Non-Specific Code Type 1 Excludes*Kaposis sarcoma of lung ... C34.30 Malignant neoplasm of lower lobe, unspecified bronchus or lung C34.31 Malignant neoplasm of lower lobe, right bronchus ... C34.32 Malignant neoplasm of lower lobe, left bronchus or lung C34.8 Malignant neoplasm of overlapping sites of bronchus and ...
... and metastatic lung malignancies. One hundred cases representing different types of neoplasms involving the anterior ... CK5/6 was a sensitive but not a specific IHC marker for the epithelial component of thymic neoplasms (100%); TTF-1 had a good ... An IHC panel consisting of CD5, CK5/6, PLAP, TTF-1, and CD57 is useful for the separation of thymic neoplasms from other ... and CD57 for the separation of thymic neoplasms from germ cell tumors (GCTs) ...
... apart from malignant neoplasms of the lung, it may also be of use in a large number of pathological conditions of the lung. We ... can be made today from chest radiograms or CT scan of the chest in a significant number of cases of secondary lung neoplasm. ... information on small improvements or deteriorations in the great majority of patients with malignant neoplasms of the lung ... The evaluation of low-intensity reduction in the compliance of the lung parenchyma (LIRCLP) can, we believe, give early ...
Extrapulmonary neoplasms in lung cancer screening. In: Translational Lung Cancer Research. 2018 ; Vol. 7, No. 3. pp. 368-375 ... Extrapulmonary neoplasms in lung cancer screening. Translational Lung Cancer Research. 2018 Jun 1;7(3):368-375. Available from ... title = "Extrapulmonary neoplasms in lung cancer screening",. abstract = "A significant reduction in lung cancer specific ... Extrapulmonary neoplasms in lung cancer screening Translational Lung Cancer Research, vol. 7, no. 3, pp. 368-375. DOI: ...
While lung cancer is the most common cause of malignant lesions in the lungs, many other malignant and benign lung neoplasms ... Beware: there are other diseases that can mimic lung neoplasms:*How and/or why did the patient develop a lung neoplasm?*Which ... Beware: there are other diseases that can mimic lung neoplasms:. Granulomatous lung diseases are the most common mimickers of ... Other Lung Neoplasms (including benign lung tumors, inflammatory pseudotumor/plasma cell granuloma, neuroendocrine tumors, ...
  • Also searched for Lung Cancer , Cancer , Tumor and more. (clinicaltrials.gov)
  • The doctor will carry out a lung biopsy , taking a small sample of the neoplasm to examine it for signs of cancer. (wisegeek.com)
  • The treatment of a cancerous lung tumor depends on how far the cancer has progressed. (wisegeek.com)
  • Frequently, lung cancer is diagnosed at a later stage, when cancer has spread beyond the lungs to invade the chest and other organs in the body. (wisegeek.com)
  • Even with treatment, the outlook for a neoplasm which has spread is typically poor and, worldwide, lung cancer causes more deaths than any other form of cancer. (wisegeek.com)
  • Since then, only 500 other cases have been reported, most frequently found in patients with advanced cancer, particularly breast and lung cancer. (elsevier.es)
  • Clinical and morphologic characteristics of lung cancer in miners of Krivoy Rog iron-ore region and of uranium mines of Zhovti Vody. (arctichealth.org)
  • In both of groups the disease course had typical features for lung cancer. (arctichealth.org)
  • Roentgenologic changes were observed, central cancer of left and right lung was revealed by bronchoscopy method. (arctichealth.org)
  • In all the cases lung cancer was morphologically proved and classified as squamous. (arctichealth.org)
  • Rapid progression of the disease and late medical aid appealability cause the patients consulted with their doctors only at the stage of II-III, sometimes III of the disease and it makes a distinction of lung cancer in miners of iron-ore and uranium mines. (arctichealth.org)
  • In order to prevent such a late diagnostics all the miners should be referred to the group of risk on lung cancer. (arctichealth.org)
  • In 2005, an estimated 172,570 new cases of lung cancer were diagnosed in the United States alone, and a staggering 1.2 million new cases are diagnosed worldwide each year. (appliedradiology.com)
  • 1,2 The lung cancer mortality rate far surpasses the mortality rates of colon, breast, and prostate cancers combined--163,510 people are expected to die of lung cancer this year in the United States. (appliedradiology.com)
  • Primary lung cancer can be divided into several histologic types. (appliedradiology.com)
  • Non-small-cell lung cancer (NSCLC) is the most common, accounting for approximately 80% of diagnoses. (appliedradiology.com)
  • Only 20% to 33% of patients with newly diagnosed lung cancer will be eligible for surgical resection. (appliedradiology.com)
  • 13-20 Radiofrequency ablation has shown promise as a safe, minimally invasive technique that may play a complimentary role or even replace existing therapies in some patients with lung cancer. (appliedradiology.com)
  • 1) Later, the European Organisation for Research and Treatment of Cancer (EORTC) classification of cutaneous lymphoma renamed it as CD4+CD56+ hematodermic neoplasm in 2005. (thefreelibrary.com)
  • NNK treatment induced pulmonary inflammation, but not lung cancer, in the rats. (begellhouse.com)
  • Utility of immunohistochemistry in separating thymic neoplasms from germ cell tumors and metastatic lung cancer involving the anterior mediastinum. (semanticscholar.org)
  • A significant reduction in lung cancer specific mortality rate was demonstrated by the National Lung Screening Trial (NLST) in participants who had annual low-dose computed tomography (LDCT) screening. (houstonmethodist.org)
  • In addition to early detection of lung cancer, lung cancer screening (LCS) provides an opportunity to detect cardiovascular disease, pulmonary disease (such as chronic obstructive pulmonary disease and interstitial lung disease), and extrapulmonary neoplasms, such as thyroid, breast, kidney, liver, esophageal, pancreatic and mediastinal tumors. (houstonmethodist.org)
  • Considering the fact that 22.3% of the certified deaths in the computed tomography (CT) arm of the NLST trial were due to extrapulmonary malignancies, compared to 22.9% of deaths from lung cancer, it is possible that early diagnosis and treatment of clinically significant incidental findings may further decrease morbidity and mortality in screening participants. (houstonmethodist.org)
  • Translational Lung Cancer Research , 7 (3), 368-375. (houstonmethodist.org)
  • While lung cancer is the most common cause of malignant lesions in the lungs, many other malignant and benign lung neoplasms may mimic primary lung cancer. (pulmonologyadvisor.com)
  • This slideshow gives a good summary of the diagnosis of lung cancer. (amazonaws.com)
  • During my GP placement of this year a different GP to the one who normally taught us called us into his consulting room to see a lady with lung cancer and subsequent clubbing. (amazonaws.com)
  • Comparison of the main types of lung cancers: squamous, adenocarcinoma, large cell, and small cell lung cancer. (amazonaws.com)
  • of South Carolina, covers the key methods of evaluating a new lung cancer, including initial diagnosis and staging studies. (amazonaws.com)
  • This slide presentation is part of a lecture by medical oncologist and lung cancer expert Dr. Jack West, in which he covers the optimal treatment strategies for locally advanced (stage III), unresectable NSCLC. (amazonaws.com)
  • This slide presentation is part of a lecture by medical oncologist and lung cancer expert Dr. Jack West, in which he discusses the evidence supporting the current standard of adjuvant (post-operative) chemotherapy to improve survival for patients with early stage, resected NSCLC. (amazonaws.com)
  • This slide presentation is part of a lecture by medical oncologist and lung cancer expert Dr. Jack West, in which he discusses current and investigational treatment options for relapsed small cell lung cancer, with a particular focus on amrubicin. (amazonaws.com)
  • When we talk about lung cancer, we are generally referring to tumour of the bronchus. (amazonaws.com)
  • Diesel emissions and lung cancer : epidemiology and quantitative risk assessment : a special report of the Institute's Diesel Epidemiology Expert Panel. (epa.gov)
  • Health effects of passive smoking : assessment of lung cancer in adults and respiratory disorders in children : review draft. (epa.gov)
  • Approach to stage IV non-small-cell lung cancer: how to select among first-line therapy options? (lww.com)
  • Provides patients and caregivers with practical advice and personal insights from lung cancer survivors and their spouses. (phsa.ca)
  • This patient-education DVD facilitates communication, provides information and emotional support to families as they confront the diagnosis and treatment of lung cancer. (phsa.ca)
  • International Association for the Study of Lung Cancer. (phsa.ca)
  • Lung cancer : the facts / by Chris Williams. (who.int)
  • Lung cancer / edited by R. B. Livingston. (who.int)
  • Smoking and health : summary of a report of the Royal College of Physicians of London on smoking in relation to cancer of the lung and other diseases. (who.int)
  • Diagnosis of the lung cancer in polyclinics] / R. I. Wagner, A. S. Barchuk, N. N. Blinov. (who.int)
  • Respiratory health effects of passive smoking : lung cancer and other disorders, the report of the U.S. Environmental Protection Agency. (who.int)
  • Respiratory health effects of passive smoking : lung cancer and other disorders. (who.int)
  • Lung cancer] / A. Kh. (who.int)
  • asbestosis and small cell lung cancer in a clutch refabricator. (lookfordiagnosis.com)
  • OBJECTIVES: To present a case of asbestosis and small cell lung cancer caused by asbestos in a clutch refabricator. (lookfordiagnosis.com)
  • 9 Stage Specefic Treatment of Non-Small Cell lung Cancer Non Small Cell Lung Cancer: Stage 1 and 2 Lobectomy/and TLND is the primary treatment for non-small lung cancer Sublobar resection. (docplayer.net)
  • A person's chance of developing lung cancer is greatly decreased after he stops smoking, yet damage caused by some diseases may never be reversed. (reference.com)
  • The top risk factor for developing lung cancer is smoking, according to the Centers for Disease Control and Prevention. (reference.com)
  • Culmination of MG132-induced apoptosis in human lung cancer NCI-H1703 cells depends on a positive feedback of caspase activation and Mcl-1 cleavage. (cdc.gov)
  • Non-small cell lung carcinoma (NSCLC) is the leading cause of cancer death in both men and women in the United States. (cdc.gov)
  • This study was prospectively designed to evaluate a phase II study of gefitinib for non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. (nature.com)
  • Based on the IDEAL trials, gefitinib received registration approval by the US Food and Drug Administration (FDA) for the second- and third-line treatment of non-small-cell lung cancer (NSCLC) ( Siegel-Lakhai et al, 2005 ). (nature.com)
  • The Iressa ® Survival Evaluation in Lung Cancer (ISEL) trial investigated gefitinib in second- and third-line NSCLC patients to investigate the survival benefit of gefitinib monotherapy compared with placebo. (nature.com)
  • Lung cancer (SIR=1.45, 95%CI=1.11-1.87) and lymphohematopoietic cancer (SIR=1.58, 95%CI=1.00-2.37) in production workers were significantly high compared to Korean general population. (cdc.gov)
  • Stomach cancer in fettling (SRR=2.10, 95%CI=1.10-4.01) and lung cancer in molding (SRR=3.06, 95%CI=1.22-7.64) and in fettling (SRR=2.63, 95%CI=1.01-6.84) were there significant elevations compared to office workers. (cdc.gov)
  • In this study, statistically significant excess lung cancer was observed in production workers comparing to Korean general population and office workers. (cdc.gov)
  • Also, cancer morbidity of overall cancer, lung cancer and stomach cancer was significantly increased with duration of employment at ten and more years comparing to Korean general population. (cdc.gov)
  • Lung cancer is a disease in which certain cells in the lungs become abnormal and multiply uncontrollably to form a tumor . (medlineplus.gov)
  • Lung cancer may not cause signs or symptoms in its early stages. (medlineplus.gov)
  • Some people with lung cancer have chest pain, frequent coughing, blood in the mucus, breathing problems, trouble swallowing or speaking, loss of appetite and weight loss, fatigue, or swelling in the face or neck. (medlineplus.gov)
  • Lung cancer occurs most often in adults in their sixties or seventies. (medlineplus.gov)
  • Lung cancer is generally divided into two types, small cell lung cancer and non-small cell lung cancer, based on the size of the affected cells when viewed under a microscope. (medlineplus.gov)
  • Non-small cell lung cancer accounts for 85 percent of lung cancer, while small cell lung cancer accounts for the remaining 15 percent. (medlineplus.gov)
  • Non-small cell lung cancer is divided into three main subtypes: adenocarcinoma, squamous cell carcinoma, and large cell lung carcinoma. (medlineplus.gov)
  • In the United States, lung cancer is the second most commonly diagnosed cancer, after breast cancer , accounting for about one-quarter of all cancer diagnoses. (medlineplus.gov)
  • It is estimated that more than 222,500 people develop lung cancer each year. (medlineplus.gov)
  • Approximately 6.6 percent of individuals will develop lung cancer during their lifetime. (medlineplus.gov)
  • An estimated 72 to 80 percent of lung cancer cases occur in tobacco smokers. (medlineplus.gov)
  • Lung cancer is the leading cause of cancer deaths, accounting for an estimated 27 percent of all cancer deaths in the United States. (medlineplus.gov)
  • In nearly all cases of lung cancer, these genetic changes are acquired during a person's lifetime and are present only in certain cells in the lung. (medlineplus.gov)
  • Somatic mutations in many different genes have been found in lung cancer cells. (medlineplus.gov)
  • TUESDAY, March 19, 2019 (HealthDay News) -- Tecentriq (atezolizumab) has been approved by the U.S. Food and Drug Administration to treat adults with extensive-stage small cell lung cancer (ES-SCLC). (hon.ch)
  • Large cell lung carcinoma with rhabdoid phenotype (LCLC-RP) is a rare histological form of lung cancer, currently classified as a variant of large cell lung carcinoma (LCLC). (icd.codes)
  • Methods: In an IRB-approved clinical study, Xe-CT and SPECT ventilation scans were acquired for three patients including one patient with severe emphysema and two lung cancer patients treated with radiotherapy. (osti.gov)
  • The study will use an Ommaya reservoir that drains into brain metastases to deliver activated, autolous dendritic cells to the tumor lesion, for patients who are 18 - 75 years old who have brain metastases from either lung cancer or breast cancer. (clinicaltrials.gov)
  • Among actual lung cancer biomarker, HER2 remains apart. (clinicaltrials.gov)
  • There is thus a strong rational for treating HER2 mutated lung cancer patient with these drugs. (clinicaltrials.gov)
  • A clinical trial that compared erlotinib with a placebo for non-small-cell lung cancer demonstrated a survival benefit for erlotinib. (nih.gov)
  • Among patients with non-small-cell lung cancer who receive erlotinib, the presence of an EGFR mutation may increase responsiveness to the agent, but it is not indicative of a survival benefit. (nih.gov)
  • Individualized cancer therapy, mesothelioma and lung cancer. (mesothelioma.com)
  • Co-Chair of the MDACC Clinical Research Committee, Scientific Advisory Committee member, chairing session participant for American Radium Society, Chair of the Communications Committee for International Association for the Study of Lung Cancer (IASLC), Chair of the Mesothelioma Applied Research Foundation (MARF), SWOG Executive Lung Committee member, SWOG Mesothelioma Steering Committee member, DSMB for NRG Thoracic Oncology member and NRG Lung Executive Committee member. (mesothelioma.com)
  • Dr. Giaccone's research includes immunotherapy and other targeted therapy options for the treatment of lung cancer tumors and other malignancies of the chest. (mesothelioma.com)
  • Dr. Giaccone is also a co-chair for the American Society for Clinical Oncology's guidelines for advanced non-small-cell lung cancer. (mesothelioma.com)
  • Co-chair for the American Society for Clinical Oncology's guidelines for advanced non-small cell lung cancer, Director's Award from the National Cancer Institute, New Drug Development Office (NDDO) Honorary Award from the NDDO Foundation, Daniel C. Ihde Memorial Lecture Award from the National Cancer Institute, honorary member of the Hellenic and International Society of Molecular-Genomic Medicine and Research. (mesothelioma.com)
  • Methods: The CREST biorepository includes biological specimens from ( a ) patients with pleural malignant mesothelioma and lung cancer, ( b ) patients with nonneoplastic respiratory conditions, and ( c ) control subjects. (aacrjournals.org)
  • Results: As of January 31, 2008, the overall number of subjects recruited was 1,590 (446 lung cancer, 209 pleural malignant mesothelioma, and 935 controls). (aacrjournals.org)
  • Although the role of lung cancer as the leading cause of death from cancer in Western countries is well known ( 3 ), interest in pleural malignant mesothelioma has recently increased because of the expected peak of cancer incidence in the second decade of the new century ( 4 ). (aacrjournals.org)
  • Lung cancer is one of the primary indications of a PET/CT study. (scielo.cl)
  • To study effects of intensity, we apply a linear excess OR model to compare total exposure delivered at low intensity for a long period of time with an equal total exposure delivered at high intensity for a short period of time to data from a large case-control study of lung cancer. (aacrjournals.org)
  • The intensity patterns are homogeneous by histologic type of lung cancer, suggesting that observed differences in risks by histologic type are related to total smoking exposure or smoking duration and not smoking intensity. (aacrjournals.org)
  • Unraveling the molecular basis of the smoking and risk of lung cancer, including mechanisms of activation and detoxification of various constituents of tobacco smoke and the genetic basis of smoking persistence, is the focus of many current epidemiologic studies of lung cancer ( 1 ). (aacrjournals.org)
  • Using data from a large case-control study of lung cancer, we apply a model for total pack-years of exposure, which enables a more direct assessment of smoking intensity. (aacrjournals.org)
  • A respiratory-gated echo-planar diffusion-weighted pulse sequence was investigated by conducting 25 diffusion studies in seven lung cancer patients who had also undergone PET/CT. (ismrm.org)
  • Furthermore, in a lung cancer mouse model, C-Raf is essential for tumor initiation by oncogenic K-Ras G12D , whereas B-Raf is dispensable for this process. (aacrjournals.org)
  • An in vivo evaluation of the role of Ras effectors in these cancer types is limited and has only been studied in the lung thus far. (aacrjournals.org)
  • For example, the importance of the Ras/Rac axis has been validated in a K-Ras-mutant mouse model of lung cancer using conditional Rac knockout mice. (aacrjournals.org)
  • Rac deficiency strongly impaired Ras tumorigenesis in the lung and developing tumors invariably retained wild-type Rac ( 7 ), suggesting an essential contribution of Rac to K-Ras G12D -initiated lung cancer. (aacrjournals.org)
  • These mutants exquisitely activate the MAPK pathway and have been observed in cancer types that frequently carry Ras mutations, for example, in melanoma (N-Ras) as well as in lung, colon, and ovary (K-Ras) ( 9 ). (aacrjournals.org)
  • Furthermore, the occurrence of activated extracellular signal-regulated kinase (ERK)1/2 in lung cancer specimens is associated with a poor prognosis ( 10 ). (aacrjournals.org)
  • In addition, pharmacological inhibition of both MEK and PI3K/target of rapamycin ( 11 ) in a K-Ras-mutant mouse model of early lung cancer ( 12 ) resulted in tumor regression, indicating that concurrent targeting of these pathways may have clinical benefits. (aacrjournals.org)
  • Prestwich, from Salt Lake City, has flown 20 missions in the past year, which have included flying a little girl from Saratoga Springs to Los Angeles for retinal blastoma treatment, transporting a healthcare professional going to Native American tribes to perform cancer screenings and promote education, and flying a Wendover, UT man to receive treatment for Lung Cancer. (thefreedictionary.com)
  • Bach P, Mirkin J, Oliver T, Azzoli C, Berry D, Brawley O. Benefits and harms of CT screening for lung cancer: a systematic review. (cdc.gov)
  • Our goal is to provide as much information as possible about Lung Cancer treatments. (omgcb.com)
  • We only send notifications regarding important Lung Cancer news. (omgcb.com)
  • BACKGROUND: Metastatic pancreatic tumors from lung cancer (MPTLC) constitute 3% of all metastatic pancreatic tumors. (omgcb.com)
  • CASE PRESENTATION: The patient was a 74-year-old woman who underwent lobectomy of lung cancer 2 years before presentation to our hospital. (omgcb.com)
  • According to histopathological and immunohistochemical findings, the tumors were diagnosed as metastatic pancreatic tumors from lung cancer. (omgcb.com)
  • Lung cancer is the leading cause of cancer deaths in the U.S. and worldwide. (nih.gov)
  • The 2 major forms of lung cancer are nonsmall cell lung cancer and small cell lung cancer (see 182280), which account for 85% and 15% of all lung cancers, respectively. (nih.gov)
  • Nonsmall cell lung cancer can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. (nih.gov)
  • Cigarette smoking causes all types of lung cancer, but it is most strongly linked with small cell lung cancer and squamous cell carcinoma. (nih.gov)
  • Nonsmall cell lung cancer is often diagnosed at an advanced stage and has a poor prognosis (summary by Herbst et al. (nih.gov)
  • To explore the serum level of inflammatory cytokines during chemotherapy among lung cancer patients. (bioportfolio.com)
  • Patients with lung cancer experience different feelings and reactions, based on their family, social, cultural, and religious backgrounds, which are a source of great distress, not only for the patients but also for their family caregivers. (scielo.br)
  • This study aimed to evaluate the impact that lung cancer stage and quality of life (QoL) of lung cancer patients have on caregiver burden. (scielo.br)
  • The burden, QoL, level of anxiety, and level of depression of caregivers were more affected by the QoL of the patients than by their lung cancer stage. (scielo.br)
  • Caregiver burden is more affected by patient QoL than by lung cancer stage. (scielo.br)
  • Advances in diagnostic and treatment strategies for lung cancer (LC), together with an increasing, aging population have resulted in a shift from impatient to outpatient treatment, underscoring the importance of family caregivers. (scielo.br)
  • The first-in-human study with NBE-002 is expected to commence by mid-2020, focusing on triple negative breast cancer and lung cancer, as well as including other solid cancer indications and lymphomas. (pharmiweb.com)
  • Determine the objective tumor response rate and duration of response in patients with progressive locally advanced or metastatic non-small cell lung cancer treated with soblidotin as second-line therapy after receiving prior platinum-based chemotherapy. (bioportfolio.com)
  • Lung cancer is the number one cancer killer in the USA. (bioportfolio.com)
  • Early stage lung cancer is asymptomatic. (bioportfolio.com)
  • Most patients with lung cancer are usually symptomatic at diagnosis and already have advanc. (bioportfolio.com)
  • RATIONALE: Doctors can diagnose lung cancer by collecting mucus coughed up from the lungs and examining it under a microscope to look for cancer cells. (bioportfolio.com)
  • The study goal is to collect blood samples from individuals at risk for lung cancer in order to identify protein markers for diagnosis of lung cancer in the Chinese population. (bioportfolio.com)
  • Cost-utility analysis of a potential lung cancer screening program for a high-risk population in Germany: A modelling approach. (bioportfolio.com)
  • Lung cancer is the leading cause of cancer death in Germany. (bioportfolio.com)
  • Although several randomized trials in Europe have evaluated the effectiveness of lung cancer screening programs, evidence on the cost-effec. (bioportfolio.com)
  • Lung Cancer Among Women in the United States. (bioportfolio.com)
  • November marks Lung Cancer Awareness Month, and reminds us that lung cancer is the leading cause of cancer death among women in the United States. (bioportfolio.com)
  • Lung Cancer: One Disease or Many. (bioportfolio.com)
  • Lung cancer is classified as a single entity comprised of multiple histological subtypes. (bioportfolio.com)
  • An Update on the European Lung Cancer Screening Trials and Comparison of Lung Cancer Screening Recommendations in Europe. (bioportfolio.com)
  • While lung cancer screening has been implemented in the United States, it is still under consideration in Europe. (bioportfolio.com)
  • Lifetime Smoking History and Risk of Lung Cancer: Results From the Framingham Heart Study. (bioportfolio.com)
  • The relative risk of lung cancer decreases with years since quitting (YSQ) smoking, but risk beyond 25 YSQ remains unclear. (bioportfolio.com)
  • Current lung cancer screening guidelines, which exclude smokers with more th. (bioportfolio.com)
  • This page covers risks: Smoking (causes nearly 9 out of 10 cases) and other causes including exposure to radon gas, certain other chemicals, air pollution, previous lung disease, a family history of lung cancer. (cancerindex.org)
  • Following smoking radon is the second leading cause of lung cancer. (cancerindex.org)
  • An international group of lung cancer researchers, established in 2004 with the aim of sharing comparable data from ongoing lung cancer case-control and cohort studies and biological samples/data to understand the genetic epidemiology of lung cancer. (cancerindex.org)
  • Over 270 lung cancer families are registered to date. (cancerindex.org)
  • TAKD is a professional association for lung cancer and tobacco control established in 2003. (cancerindex.org)
  • The society represents multidisciplinary approach in the lung cancer care policy and education. (cancerindex.org)
  • The preventive effects of hyperoside on lung cancer in vitro by inducing apoptosis and inhibiting proliferation through Caspase-3 and P53 signaling pathway. (cancerindex.org)
  • Though advanced surgical operation and chemotherapy have been under taken, lung cancer remains one of the most aggressive and fatal human malignancies with a low survival rate. (cancerindex.org)
  • Thus, novel therapeutic strategies for prevention and remedy are urgently needed in lung cancer. (cancerindex.org)
  • In the study, we attempted to investigate whether hyperoside could inhibit lung cancer progression via Caspase-3- and P53-regulated cell death. (cancerindex.org)
  • Our data suggested that hyperoside exerted inhibitory role in lung cancer development. (cancerindex.org)
  • Inhibition of NF-κB transcriptional activity, Caspase-9/Caspase-3 activation, the cell cycle arrest, and suppression of cell proliferation-related signaling pathway led to the lung cancer inhibition. (cancerindex.org)
  • To determine the demographic and clinical characteristics of patients with non-small cell lung cancer (NSCLC), as well as their disease course, by age group and gender. (scielo.br)
  • These include: Primary tumors of the lung/pulmonary system: Bronchial leiomyoma, a rare, benign tumor Lung cancer, the term commonly used to refer to carcinoma of the lung Pulmonary carcinoid tumor Pleuropulmonary blastoma Neuroendocrine tumors of the lung Lymphomas of the lung. (wikipedia.org)
  • A suture granuloma was resected which developed after segmentectomy of a squamous cell carcinoma of the lung and radiologically mimicked a neoplasm. (bmj.com)
  • In general, most lung cancers arise from the bronchial epithelium (giving the generic term 'bronchiogenic carcinoma') and are most commonly found around the hilium of the lung (ex. (brainscape.com)
  • Role of PAX-8, CD5, and CD117 in distinguishing thymic carcinoma from poorly differentiated lung carcinoma. (semanticscholar.org)
  • Uncommon primary malignant tumors of the lung include carcinoid (neuroendocrine tumor) and salivary gland tumors of adenoid cystic carcinoma and mucoepidermoid carcinoma. (pulmonologyadvisor.com)
  • 95% of lung cancers are carcinoma of the bronchus 2% are alveolar tumours 3% are benign or less invasive malignant tumours. (amazonaws.com)
  • Case report of lymphoepithelioma-like carcinoma of the lung --lymphoid population consisting of cytotoxic T cells in resting state. (lookfordiagnosis.com)
  • The present report describes a case of lymphoepithelioma-like carcinoma (LELC) of the lung and presents immunohistochemical and in situ hybridization (ISH) studies of the tumor. (lookfordiagnosis.com)
  • Necropsy lung tissue showed grade 4 asbestosis and a small cell carcinoma in the right pulmonary hilum. (lookfordiagnosis.com)
  • In a prior Phase Ib study, this combination of agents exhibited antitumor effects in the lungs of four of eight patients with renal cell carcinoma and pulmonary metastases. (lookfordiagnosis.com)
  • Large cell carcinoma arises from epithelial cells that line the lungs. (medlineplus.gov)
  • Large cell carcinoma encompasses non-small cell lung cancers that do not appear to be adenocarcinomas or squamous cell carcinomas. (medlineplus.gov)
  • From this group of dogs, 4 out of 5 neoplasms (80%) were diagnosed as complex carcinoma by histopathology diagnosis. (unicordoba.edu.co)
  • We provide evidence suggesting that complex carcinoma is the most frequent mammary tumor in bitches in our city and it is highly related to lung metastasis. (unicordoba.edu.co)
  • Salivary gland-type lung carcinomas are uncommon neoplasms from the lung both most common getting adenoid cystic carcinoma and mucoepidermoid carcinoma. (movd2016.org)
  • Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung. (nih.gov)
  • Carcinoma of lung with rhabdoid features. (nih.gov)
  • Zheng G, Ettinger DS, Maleki Z. Utility of the quantitative Ki-67 proliferation index and CD56 together in the cytologic diagnosis of small cell lung carcinoma and other lung neuroendocrine tumors. (hopkinsmedicine.org)
  • Investigate predictive models for long-term tumor control and late treatment lung toxicity by using FDG-PET-CT, V/Q SPECT-CT and blood test during the course of radiation therapy. (clinicaltrials.gov)
  • Perhaps the most important of these is whether the tumor is a benign lung neoplasm or a malignant lung neoplasm. (wisegeek.com)
  • Where there is any doubt about a tumor being benign, lung surgery is usually carried out to remove the lump. (wisegeek.com)
  • CONCLUSIONS: Tumor-infiltrating lymphocytes are observed in about one fourth of resected lung neoplasms: they are rare in neuroendocrine tumors. (unito.it)
  • Because LELC of the lung responded to preoperative chemotherapy in the present study, it may be useful for reducing the local tumor burden and facilitate subsequent local therapy, although the mechanism of chemosensitivity of LELC remains unknown. (lookfordiagnosis.com)
  • Gastrointestinal stromal tumor masquerading as a lung neoplasm. (biomedcentral.com)
  • Purpose: Accurately localizing lung tumor localization is essential for high-precision radiation therapy techniques such as stereotactic body radiation therapy (SBRT). (osti.gov)
  • Since direct monitoring of tumor motion is not always achievable due to the limitation of imaging modalities for treatment guidance, placement of fiducial markers on the patient's body surface to act as a surrogate for tumor position prediction is a practical alternative for tracking lung tumor motion during SBRT treatments. (osti.gov)
  • Conclusions: The PCA model is an accurate, efficient, robust, and practical model for solving the multimarker position optimization problem to predict lung tumor motion during SBRT treatments. (osti.gov)
  • gene somatic mutations in the tyrosine-kinase encoding exons (18-21) of non-small-cell lung carcinomas mostly adenocarcinomas and tumor response.7 8 However amplification of by fluorescent hybridization (FISH) had not been only connected with tumor response but also overall survival.9 Although expression of EGFR discovered by immunohistochemistry is common it generally does not may actually correlate with tumor response but could be useful being a testing test. (movd2016.org)
  • For locations such as the lung and the pleura, tumor specimens are difficult to obtain. (aacrjournals.org)
  • Quantitative MR diffusion imaging provides delineation of viable lung tumor and exhibits excellent correspondence with PET imaging. (ismrm.org)
  • Types of lung cancers. (brainscape.com)
  • Regardless of subtype, all lung cancers tend to appear macroscopically as irregular, heterogeneous tumours that are grey, yellow or brown in appearance. (brainscape.com)
  • Somatic mutations in the TP53 , EGFR , and KRAS genes are common in lung cancers. (medlineplus.gov)
  • Tsao has also performed studies involving smoking history and its impact on the prognosis of those with non-small cell lung cancers like mesothelioma. (mesothelioma.com)
  • Studies of smoking and cancers of the lung and the bladder show a leveling of risk for smokers consuming more than 20 to 40 cigarettes per day ( 9 , 10 ). (aacrjournals.org)
  • Immunohistochemistry in the diagnosis of thymic epithelial neoplasms. (semanticscholar.org)
  • The evaluation of low-intensity reduction in the compliance of the lung parenchyma (LIRCLP) can, we believe, give early diagnostic signs from a few months to two or more years before the time at which diagnosis can be made today from chest radiograms or CT scan of the chest in a significant number of cases of secondary lung neoplasm. (semanticscholar.org)
  • To code a diagnosis of this type, you must use one of the three child codes of C34.3 that describes the diagnosis 'malignant neoplasm of lower lobe, bronchus or lung' in more detail. (icd.codes)
  • Regional lung ventilation information may be useful for the diagnosis and monitoring of pulmonary diseases such as COPD, radiotherapy planning, and assessing the progression of toxicity after radiation therapy. (osti.gov)
  • C34.30 is a billable ICD code used to specify a diagnosis of malignant neoplasm of lower lobe, unspecified bronchus or lung. (icd.codes)
  • Usefulness of Cdx2 in separating mucinous bronchioloalveolar adenocarcinoma of the lung from metastatic mucinous colorectal adenocarcinoma. (semanticscholar.org)
  • Some rare vascular tumors of the lung Non-lung tumors which may grow into the lungs: Mediastinal tumors Pleural tumors Metastasis or secondary tumors/neoplasms with other origin: Metastasis to the lung Lung nodule Horn L, Lovly CM (2018). (wikipedia.org)
  • Causes of inflammatory lung diseases include smoking, asbestos, and air pollution and irritants, according to the Office of Women's Health. (reference.com)
  • Moreover, the case studies on lung neoplasms and prostate neoplasms also illustrate that BRWHNHA is superior to previous prediction methods and is more advantageous in exploring potential miRNAs related diseases. (nature.com)
  • A variety of primary and metastatic neoplasms can involve the anterior mediastinum and have similar radiographic or histologic appearances. (semanticscholar.org)
  • We report an immunohistochemical (IHC) panel that includes CD5, placental-like alkaline phosphatase (PLAP), thyroid transcription factor 1 (TTF-1), cytokeratin (CK) 7, CK20, CK5/6, and CD57 for the separation of thymic neoplasms from germ cell tumors (GCTs) and metastatic lung malignancies. (semanticscholar.org)
  • A primary or metastatic malignant neoplasm involving the lung. (nih.gov)
  • IMSEAR at SEARO: Diagnostic value of needle biopsy of lung in pulmonary neoplasm. (who.int)
  • KRASG12D expression in lung-resident myeloid cells promotes pulmonary LCH-like neoplasm sensitive to statin treatment. (cdc.gov)
  • Using a mouse model expressing KRAS G12D in the lung by nasal delivery of adenoviral Cre recombinase (Cre), here we show that KRAS G12D expression in lung-resident myeloid cells induces pulmonary LCH-like neoplasms composed of pathogenic CD11c high F4/80 + CD207 + cells. (cdc.gov)
  • These precursors were derived, at least in part, from CD11c dim CD11b int Gr1 - lung-resident monocytic cells transformed by KRAS G12D In contrast, BRAF V600E expression induced by the same method failed to develop LCH-like neoplasms, suggesting that each oncogene may initiate pulmonary LCH by transforming different types of lung-resident myeloid cells. (cdc.gov)
  • As the lungs are compressed and distended by the respiratory muscles, the pressure within the alveoli (intra-alveolar pressure) rises and falls. (thefreedictionary.com)
  • DRG Group #180-182 - Respiratory neoplasms with MCC. (icd.codes)
  • Immunoexpression of epidermal development aspect receptor in salivary gland-type lung carcinomas isn't linked to epidermal development aspect receptor gene duplicate amount or mutational position. (movd2016.org)
  • Neuroendocrine tumors from the lung including little cell carcinomas will not exhibit EGFR13 and so are virtually always detrimental for mutation.14 Although EGFR expression continues to be reported in salivary gland carcinomas of the top and throat 15 little is well known about mutation amplification and expression in salivary gland-type tumors from the lung. (movd2016.org)
  • the gene the incident of amplification as well as the EGFR appearance in adenoid cystic carcinomas and mucoepidermoid carcinomas from the lung. (movd2016.org)
  • Between 1972 and 2002 62 salivary gland-type lung carcinomas had been discovered in the Mayo Medical clinic Rochester information and detailed outcomes published.3 Of the situations 24 (12 adenoid cystic carcinomas and 12 mucoepidermoid carcinomas) were CHR2797 preferred for this research predicated on the option of specimens from surgical resections or huge biopsy specimens and quality of tissues. (movd2016.org)
  • A recent National Tox icology Program study showed B6C3F1 mice exposed to TCAB developed a treatment-related increase in lung carcinomas in the high-dose group, and urethral carcinomas, an extremely rare lesion in rodents, in all dose groups. (21centurytoxicology.com)
  • Alternative epithelial markers in sarcomatoid carcinomas of the head and neck, lung, and bladder-p63, MOC-31, and TTF-1. (nih.gov)
  • Thyroid transcription factor-1 is a marker of lung and thyroid carcinomas. (nih.gov)
  • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified ( C25.9 ). (icd10data.com)
  • TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, RB1 Mutation, and TP53 Exon 5 Mutation are the most common alterations in lung neuroendocrine neoplasm [ 2 ]. (mycancergenome.org)
  • Protecting each lung is the pleura, a two-layered membrane that envelops the lung and contains lubricating fluid between its inner and outer layers. (thefreedictionary.com)
  • Sarcomatoid neoplasms of the lung and pleura. (nih.gov)
  • K-Ras is the predominantly mutated Ras family member, and activating mutations in K-Ras are associated primarily with malignancies of the lung, pancreas, and colon. (aacrjournals.org)
  • In this article, we report a case of BDPCN presenting with skin, lymph node, bone marrow, peripheral blood, lung, and central nervous system involvement and have reviewed the literature since the latest WHO classification of tumors of hematopoietic and lymphoid tissue in 2008 to delineate the characteristics of the disease. (thefreelibrary.com)
  • The Endocrine lung in health & disease / [edited by] Kenneth L. Becker, Adi F. Gazdar. (who.int)
  • Secondhand smoke, pollution, radon and asbestos are linked to lung disease. (reference.com)
  • What Are Some Causes of Inflammatory Lung Disease? (reference.com)
  • There are 14 clinical trials for lung neuroendocrine neoplasm, of which 10 are open and 4 are completed or closed. (mycancergenome.org)
  • SSTR2, SSTR1, and SSTR3 are the most frequent gene inclusion criteria for lung neuroendocrine neoplasm clinical trials [ 3 ]. (mycancergenome.org)
  • Nivolumab, 177lu-dotatoc, and 177lu-opsc001 are the most common interventions in lung neuroendocrine neoplasm clinical trials. (mycancergenome.org)
  • A chest X-ray was performed and revealed a mass in the lower lobe of the right lung. (elsevier.es)
  • To define the presence of lung metastasis in bitches with malignant mammary neoplasms. (unicordoba.edu.co)
  • Latero-lateral and ventral-dorsal radiographic images of thorax were done for identification of radiographic lesions suggestive of lung metastasis. (unicordoba.edu.co)
  • Five out of 30 bitches (16.6%) had lung metastasis according to radiographic examination. (unicordoba.edu.co)
  • A benign lung neoplasm is much rarer than a cancerous one, and benign neoplasms account for up to five percent of cases where a lump is found in the lungs. (wisegeek.com)
  • Maleki Z. Diagnostic issues with cytopathologic interpretation of lung neoplasms displaying high-grade basaloid or neuroendocrine morphology. (hopkinsmedicine.org)
  • Langerhans cell histiocytosis (LCH) is a rare histiocytic neoplasm associated with somatic mutations in the genes involved in the RAF/MEK/extracellular signal-regulated kinase (ERK) signaling pathway. (cdc.gov)
  • Popper, Helmut H. / Molecular genetics of lung and pleural neoplasms . (uthscsa.edu)
  • Bronchial carcinoid tumors account for 2% to 5% of all lung malignancies and 20% of all carcinoid tumors. (pulmonologyadvisor.com)
  • Based on autopsy reports, lung metastases occur in 33% to 50% of all non-lung malignancies. (pulmonologyadvisor.com)
  • Emphysema, COPD and chronic bronchitis cause scarring of the lung tissue, which is permanent. (reference.com)
  • Cancerous neoplasms may be treated with surgery, chemotherapy and radiation therapy , alone or in combination. (wisegeek.com)
  • This study was designed to determine whether fenofibrate, a PPARα agonist, can suppress 4-nitroquinoline 1-oxide (4-NQO)-induced proliferative lesions in the lung of obese hyperlipidemic mice. (mdpi.com)
  • Male Tsumura Suzuki Obese Diabetic mice were subcutaneously injected with 4-NQO to induce lung proliferative lesions, including adenocarcinomas. (mdpi.com)
  • Our results indicate that fenofibrate can prevent the development of 4-NQO-induced proliferative lesions in the lung by modulating the insulin-IGF axis. (mdpi.com)
  • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. (icd10data.com)